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Chapter 1
During the past decade interventional oncology (IO) has gained prominence as 
a minimally-invasive cancer treatment besides surgery, external beam radiation 
and systemic therapy. IO procedures can be applied in the curative setting 
to obtain local control or in the palliative setting for symptom control. [1] This 
thesis investigates the value of IO procedures for liver metastatic breast cancer 
(LMBC) and renal tumours.
Part I: Intra-arterial therapies for liver metastatic breast cancer
During intra-arterial liver-directed therapies, local drugs are administrated in 
the hepatic arteries to deliver high local doses at low systemic toxicities. The 
dual blood supply of the liver, in which the metastases are supplied mainly 
by the liver arteries and the liver parenchyma by the portal vein, ensures 
that the drugs target the liver metastases while sparing the healthy liver 
parenchyma [2].
Currently, intra-arterial therapies are increasingly adopted as a treatment 
alternative for chemo-refractory patients, suffering from primary liver tumours, 
neuroendocrine neoplasms and colorectal liver metastases (CRLM), not eligible 
for surgery [3-5]. In patients with liver metastatic breast cancer (LMBC), intra-
arterial therapies have so far been less commonly studied for use in clinical 
practice.
Compared to other neoplasms, LMBC patients present with more extensive 
extra-hepatic disease and are subsequently stratified for standard systemic 
treatment. Challenges of systemic treatment are failure to control toxicity and 
chemo-resistance after several lines of chemotherapeutic agents. In addition, 
the liver metastases often cause hepatic dysfunction affecting the efficacy 
and safety of systemic chemotherapy and is, therefore, often a dose-limiting 
factor. A break from systemic treatment (chemo holiday) may be beneficial 
for patients to recover from systemic therapy [6). Intra-arterial therapies can 
be considered to provide this chemo holiday in LMBC patients with stable 
extra-hepatic disease or provide a treatment option in chemo-refractory LMBC 
patients. [7]
Several intra-arterial therapies are available, including trans-arterial 
radioembolization (TARE), trans-arterial chemoembolization (TACE) and chemo 
infusion. During TACE and chemo infusion, high doses of chemotherapeutic 
agents are administered locally, and in TACE this infusion is performed along 
with an occlusion of the supplying arteries. TARE, on the other hand, uses 
BrigitAarts_BNW.indd   8 08/09/2020   14:27:41
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radioactively-labelled microspheres with Yttrium-90 that emits radiation after 
emission of β- particles (electrons) with only a temporary occlusive effect [8]. 
The differences between these therapies with regards to efficacy and safety 
in LMBC have so far not been investigated and consequently these treatments 
have not yet been included in the guidelines for advanced breast cancer [9].
Mitomycin C (MMC) was a standard chemotherapy that was initially administered 
intravenously as a systemic treatment for breast cancer patients [10]. To date, 
MMC is no longer applied as a systemic agent in metastatic breast cancer, 
due to new upcoming chemotherapeutics and the serious, but rarely observed, 
adverse event hemolytic uremic syndrome (HUS) [11]. If MMC is infused intra-
arterially, a high first-pass effect is observed locally within the liver at minimal 
systemic toxicities. In 2007, Maes et al. reported the safety and efficacy of MMC 
arterial infusion in 30 LMBC patients, without any cases of HUS [12].
Small retrospective reports of TARE in LMBC show promising results with a 
disease control rate above 78% [13]. To further increase the survival of LMBC 
patients, a combination of TARE and MMC infusion might have the potential 
to be more effective than intra-arterial MMC or TARE on its own. The safety 
of patients treated with a sequence of different intra-arterial therapies have 
been reported in primary liver tumours [14]. To date, no reports are available 
for the sequential infusion of TARE and systemic or local chemotherapy in 
LMBC patients.
Part II: Percutaneous ablation in renal cell cancer
The incidence of renal cell carcinoma (RCC) has risen during the last decade, 
due to the expansion of imaging modalities and accidental diagnosis of (small) 
renal masses. Yet, the mortality rates of RCC are stable in developed countries. 
A minimal invasive treatment approach could be an alternative to (partial) 
nephrectomy obtaining optimal local control while sparing kidney function. 
[15]. One of the IO procedures that is increasingly adopted is percutaneous 
thermal ablation. Here, needles are inserted under image guidance to target 
tumoural lesions and achieve tumour death using extremely high (100 ° C) or 
low temperatures (-100 ° C). Ablative treatment has proven to be as effective 
as resection in patients with a small RCC limited to the kidney (stage I disease) 
who are not eligible for surgery [16, 17].
Most renal masses show malignant characteristics on computed tomography 
(CT), but up to 30% are found to be benign after (partial) nephrectomy raising 
1
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the concern of overtreatment in small renal masses [18]. In patients scheduled 
for ablation, a renal mass biopsy (RMB) to obtain histological diagnosis is often 
performed during the same session prior to the ablative procedure. Although 
recent guidelines recommend to perform the biopsy in a separate session [16], 
in daily practice many centers prefer to do this immediately prior to the ablation. 
There is limited and conflicting data supporting the one or the other biopsy 
strategy with respect to outcome, nor are the rates of overtreatment reported 
in large multicenter studies.
Radiofrequency ablation (RFA) and cryoablation (CA) are the most frequently 
applied ablative techniques. Microwave ablation (MWA) is a recent technique 
and still considered experimental in the European Association of Urology 
guidelines for RCC. [19-22] Reports about the efficacy and safety of large 
cohorts of MWA are scarce, especially for T1b tumours [23, 24]. The R.E.N.A.L 
nephrometry score objectifies critical anatomical features of renal masses and 
predicts surgical complications after (partial) nephrectomy. Since lower efficacy 
rates after ablation are reported in tumours over 3 cm, a modified version of 
the R.E.N.A.L nephrometry score is used. Ierardi et al. suggested that this 
modified version might be predictive for oncological outcome after MWA [25].
For residual disease after percutaneous ablation or recurrence during the follow 
up after successful treatment, several salvage treatment options are available 
including repeat ablation and (partial) nephrectomy (PN). Surgery after ablation 
is technically challenging due to the perinephric scarring that hampers kidney 
mobilization. In addition, recurrences located centrally carry the risk for urine 
leakage with PN [26]. In many cases, a repeated thermal ablation is therefore 
chosen as the preferred salvage treatment modality [27]. Because the residual 
tumour occurs particularly near the renal sinus or renal vessels, CA is the 
preferred ablation technique for a better protection of the urothelial architecture 
compared to heat-based ablation techniques [28, 29]. Additionally, during the 
CA procedure itself, optimal visualization of the ablation zone is obtained, which 
better provides information on the ablative margins.
In 1950, a systemic effect away from the ablated tissue was described after 
CA of the prostate, also known as the abscopal effect [30]. Compared to 
heat-producing modalities such as MWA and RFA, CA leaves the intracellular 
contents intact after cell destruction and provides the best environment for 
the immune system. However, this abscopal effect occurs rarely and is only 
described in case series. Hypothetically the immune initiation after ablation can 
be enhanced by immune checkpoint inhibitors. In recent years, the introduction 
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of immune checkpoint inhibitors has gained a remarkable survival benefit in 
specific cancer types such as stage IV melanoma patients [31]. Unfortunately, 
not all patients respond to immunotherapy and preliminary animal studies 
suggest that percutaneous CA may help to increase the effectiveness of 
immunotherapy in stage IV disease because of its abscopal effect.
Aim of this thesis
The aim of this thesis is to report outcomes of intra-arterial and ablative 
procedures regarding safety and efficacy and to optimize the treatments by 
evaluating factors influencing the oncological outcome.
The main questions of this thesis are:
1. What is the role of intra-arterial therapies in LMBC patients?
1a.  what is the safety and efficacy of intra-arterial MMC infusion?
1b.  what are the factors influencing overall survival after intra-arterial 
MMC infusion?
1c.  is sequential intra-arterial administration of MMC after TARE 
feasible and safe?
2. How can we optimize oncological outcomes after percutaneous ablation 
in RCC patients?
2a. what is the impact of different biopsy strategies for patients with 
a renal mass scheduled for ablation?
2b. what is the efficacy of MWA in T1 RCC and what are the factors 
influencing the outcome?
2c. is CA feasible in residual or recurrent disease following MWA?
2d. what is the evidence of the effect of CA on the immune system 
and its synergy with immunotherapy?
Outline of this thesis
Part I: Intra-arterial therapies for liver metastatic breast cancer patients
In Chapter 2, the differences between intra-arterial therapies for LMBC patients 
are systematically evaluated. The safety, efficacy and factors influencing the 
overall survival of MMC intra-arterial infusion in LMBC patients are described 
in Chapter 3. Chapter 4 assesses whether it is feasible and safe to sequentially 
and intra-arterially administer MMC after TARE in LMBC patients.
1
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Part II: Percutaneous ablation in renal cell cancer
Chapter 5 evaluates different biopsy strategies for patients with a renal mass 
planned for an ablation. In Chapter 6 the outcome and factors influencing the 
outcome of MWA in T1 RCC are evaluated. The feasibility to perform CA after 
MWA is assessed in Chapter 7. Chapter 8 shows the available evidence of the 
synergy between CA and the immune system.
BrigitAarts_BNW.indd   12 08/09/2020   14:27:41
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ABSTRACT
Purpose: The aim of this study was to determine the safety and efficacy of 
Mitomycin C (MMC) infusion in a large cohort of advanced liver metastatic 
breast cancer patients (LMBC) and to determine factors influencing overall 
survival (OS).
Methods: We retrospectively analysed LMBC patients, treated with MMC 
infusion between 2000 and 2017. Hepatic response was measured with 
baseline CT scans and first available CT scan after MMC infusion by RECIST 
1.1 criteria. Adverse events were registered by the CTCAE version 5.0. OS and 
hepatic progression free survival (hPFS) were evaluated using Kaplan Meier 
estimates. After univariable analysis, a stepwise forward multivariable (MV) 
prediction analysis was developed to select independent pre-treatment factors 
associated with OS.
Results: We included 176 patients with a total of 599 MMC infusions, mostly 
heavily pre-treated patients with a median time from diagnosis of MBC to MMC 
infusion of 36.9 months. RECIST evaluation of liver lesions (n=132) showed a 
partial response rate of 15%, stable disease of 43% and progressive disease in 
17%. Adverse events grade 3 and 4 were reported in 17.5%. Median hPFS was 
5.5 months and median OS was 7.8 months. Significant independent baseline 
predictors of worse OS included number of prior systemic chemotherapy lines, 
prior liver ablation, higher liver tumour burden, and elevated levels of bilirubin 
and ALT.
Conclusion: MMC infusion is safe and effective in advanced LMBC patients. 
An increased number of prior therapies, a higher liver tumour burden and 
elevated levels of bilirubin and ALT were associated with a worse OS.
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INTRODUCTION
Breast cancer is the world leading type of cancer in women [1]. Localized 
breast cancer has a 5 year survival rate around 99% [2]. However, about 
20-30% of women with breast cancer develop metastases at some point, which 
dramatically worsens the prognosis with a 5-year survival rate of 25% (all 
metastatic sites included) [3]. Liver metastatic breast cancer (LMBC) eventually 
occurs in 50% of metastatic breast cancer patients and is associated with 
worse prognosis of only a few years [4, 5].
In most cases the initial therapy for LMBC is systemic treatment by means of 
chemotherapy with taxanes or anthracyclines [6]. The efficacy and safety of 
the systemic chemotherapy can be affected by the hepatic dysfunction caused 
by the metastases which is therefore often a dose limiting factor [7, 8]. Local 
intra-arterial therapies can offer higher local concentration of chemotherapy to 
the liver metastases with less systemic effect due to the arterial blood supply 
of the metastases [9, 10].
Mitomycin C (MMC) is a classical chemotherapeutic agent that was originally 
used as a intravenously administered chemotherapeutic agent for systemic 
treatment of breast cancer [11]. Due to some rare, but severe systemic 
toxicities like the haemolytic uremic syndrome (HUS), and new upcoming 
other chemotherapeutics like anthracyclines and taxanes, the use of systemic 
intravenously administered Mitomycin C has significantly declined in the last 
decades [12, 13]. However, when MMC is locally infused in the hepatic arteries, 
a high first pass is obtained to the metastases with minimal effects to the 
healthy parenchyma. The low systemic toxicity of MMC may provide a break 
from systemic chemotherapy to recover from the toxicities. Maes et al. showed 
the safety of intra-arterial administration of MMC without major complications 
in a small cohort [14].
The purpose of this study was to evaluate a large cohort of LMBC patients 
treated with intra-arterial infusion of MMC in order to determine safety and 
efficacy of the treatment and to determine pre-treatment factors associated 
with overall survival (OS).
3
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METHODS
Study design
This study was approved by the ethics committee of our institute (S60596). 
The requirement for an informed consent was waived, due to its retrospective 
nature. Patients with liver metastatic breast cancer treated with intra-arterial 
MMC infusion between October 2000 and December 2017 were included. All 
breast cancer patients were prospectively registered in a follow up database. 
This database plus patients records were retrospectively reviewed. Clinical 
results were analysed to obtain patients oncological history. All patients 
underwent baseline assessment of liver function, general blood count and 
coagulation factors at every cycle of MMC. Tumour burden was accessed by 
eyeballing of the total volume of tumour in the liver and was categorized as 
0-25 %, 25-50 %, >50 %.
Mitomycin C infusion
Details of the MMC infusion procedure have been previously described [14]. 
The treatment was performed by, or supervised by, an expert interventional 
radiologist. Under local anaesthesia, femoral access was generally obtained 
in the right common femoral artery and a 4-French sheath was introduced. A 
micro catheter was used through a diagnostic 4-French catheter for selective 
catheterization of the right and left hepatic artery. A starting total of 12 mg 
Mitomycin C (MMC) in a 10 cc saline solution was administered divided over 
both liver lobes according to the liver volume. Subsequent dosing was done 
every 4 weeks or longer. Doses of Mitomycin C could be adjusted by physicians 
according to clinical performance and laboratory results.
Follow-up and Response Assessment
Treatment was evaluated by the first available computed tomography (CT) scan 
after MMC infusion. We measured hepatic response by comparing the liver CT 
before and after MMC infusing according to the response evaluation criteria 
in solid tumours (RECIST) criteria 1.1 with four categories [Partial Response 
(PR), Complete Response (CR), Stable Disease (SD) and Progressive Disease 
(PD)][15]. Two hepatic target lesions were selected for the response in the liver.
The treating physician decided to continue MMC cycles based on radiological 
and biochemical results and patient performance. The maximum amount of 
MMC cycles was, in principle, 6 cycles (because of increased subsequent risk 
of HUS at higher cumulative dose); however additional MMC infusions could 
be considered in case of disease control without side effects. Administration 
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of MMC cycles was stopped in patients with progressive hepatic or extra hepatic 
disease or due to unstable clinical or biochemical characteristics. Adverse events 
were registered by the Common Terminology Criteria for Adverse Events (CTCAE) 
version 5.0 by retrospectively use of patient records and laboratory results.
Survival time was calculated from the date of first MMC cycle until death or 
loss to follow-up. Hepatic progression free survival (hPFS) was calculated from 
the first MMC cycle until hepatic progression on radiological images occurred.
Statistics
Pre-treatment patient and tumour characteristics are described as median 
and range for continuous variables and as frequencies and percentages for 
categorical variables. OS and hPFS were estimated using the Kaplan-Meier 
method starting at the date of the first cycle of MMC.
Cox proportional hazards models were used to analyse the prognostic effect of 
the pre-treatment characteristics on OS. Results are presented as hazard ratios 
(HR) with 95% confidence intervals (95% CI). Non-linear (quadratic) trends 
are tested for all continuous predictors. A forward stepwise model selection 
procedure was applied to develop a multivariable model for independent 
prognostic factors associated with OS. To specify, a significance level of 
5% was used for both entry and removal of variables: step by step individual 
variables were added to the model, selecting in each step the variable leading 
to the lowest p-value, and adding variables as long as the variable showed 
a significant p-value. Additionally, previously included variables turning non-
significant along the procedure are removed from the model. All analyses are 
two-sided and a 5% significance level is assumed for all tests. Analyses were 
performed using SAS software (version 9.4 of the SAS System for Windows) 
and Statistical Package for the Social Sciences (SPSS, version 25, Chicago, IL).
RESULTS
Patient Characteristics
Table 1 shows the pre-treatment factors of the 176 patients treated with MMC 
between 2000 and 2017. Most patients had a ductal adenocarcinoma (84%) 
with a positive oestrogen receptor (80%), a positive progesterone receptor 
(66%) and a negative Her2 status (81%). Disease was mostly metastasized 
in a metachronous manner (82%). The tumour burden of the liver was greater 
than 25% in 85 (50% of the) patients. 73% of the patients had one or more extra 
hepatic sides of metastases (bone n=98, lung n=31, non-loco regional nodes 
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n=29, abdominal n=15, pleura n=6, cutaneous n=5, mediastinal n=5, adrenal 
n=4, peritoneal n=4, brain n=4). At inclusion, patients had received a median of 
4 systemic chemotherapeutic lines (range 0-11) in the metastatic setting before 
MMC infusion. We included only systemic chemotherapies in the metastatic 
setting without hormonal, HER2 therapies or chemotherapies in the adjuvant 
or neoadjuvant setting. Median time from diagnosis of metastatic disease until 
MMC infusion was 36.9 months (SD 35.6).
Table 1. Patient pre-treatment characteristics, and univariate analysis for overall survival.
N = 176 Univariate analysis
HR (95%-CI) p value
Aetiology primary tumour 0.39
 Ductal 142 (84%)
 Lobular 21 (12%)
 Other 7 (4%)
Hormone status primary tumour
 Positive oestrogen receptor 135 (80%) 0.9 (0.6;1.3) 0.58
 Positive progesterone receptor 111 (66%) 0.96 (0.7;1.3) 0.81
 Positive HER2 receptor 29 (19%) 1.1 (0.7;1.6) 0.75
 Triple negative receptor status 18 (11%) 1.7 (1.0;2.7) 0.046
Diagnosis of liver metastasis
 Synchronous 32 (18%) Ref Ref
 Metachronous 144 (82%) 0.8 (0.6;1.2) 0.33
Time from diagnosis of breast cancer 
to liver metastases, months
36.6 (0-329.5) 1.0 (0.99;1.00) 0.80
Liver tumour burden <.0001
 < 25% 85 (50%) Ref Ref
 25%-50% 44 (26%) 2.1 (1.5;3.1) <.0001
 > 50% 41 (24%) 2.9 (2.0;4.4) <.0001
Extra hepatic sites of metastases
 Yes 129 (73%) 1.3 (0.9;1.8) 0.18
 No 47 (27%) Ref Ref
Median systemic chemotherapy lines 
for MBC before MMC
4 (0-11) 1.1 (1.1;1.2) <.0001
Prior hepatic treatment
 Surgery 9 (5%) 0.5 (0.2;0.97) 0.042
 Ablation 3 (1.7%) 5.1 (1.6;16) 0.0058
Alanine aminotransferase level
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Table 1. Continued.
N = 176 Univariate analysis
HR (95%-CI) p value
 Normal < 31 µL 58 (34%) Ref Ref
 Elevated > 31 µL 115 (66%) 1.9 (1.4;2.7) 0.0001
Bilirubin level total
 Normal < 1.18 mg/dL 153 (88%) Ref Ref
 Elevated >1.18 mg/dL 21 (12%) 2.98 (1.9;4.8) <.0001
Haemoglobin
 Normal >12 – 16 g/dL 86 (49%) Ref Ref
 Declined < 12 g/dL 89 (51%) 1.3 (0.95;1.8) 0.098
White blood count
 Normal > 4.5*10**9/L 138 (89%) Ref Ref
 Declined < 4.5*10**9/L 37 (21%) 0.8 (0.6;1.2) 0.37
Platelet count
 Normal >100*10**9/L 169 (97%) Ref Ref
 Declined <100*10**9/L 6 (3%) 2.0 (0.9;4.6) 0.098
Kidney function (eGFR)
 Normal > 60 mL/min 128 (97%) Ref Ref
 Declined < 60 mL/min 4 (3%) 0.6 (0.2;1.7) 0.36
Treatment Characteristics
Table 2 shows treatment factors of the MMC infusions. A total of 599 MMC 
cycles were given in 176 patients. The median age at first MMC infusion 
was 56 years (range 26 - 86). No patients received additional chemotherapy 
during MMC infusion. Nine patients underwent a hepatic resection and 3 
patients a percutaneous thermal ablation for their hepatic disease before 
MMC infusion. After MMC infusion was stopped for any reason (in most cases 
progression), 50% of the patients received further systemic treatment with 
other chemotherapies, and 9 (5%) patients received local hepatic treatment 
consisting of intra-arterial radioembolization with yttrium 90 (n=5), external 
beam radiotherapy (n=1), percutaneous thermal ablation (n=1) and surgery 
(n=2).
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Table 2. Treatment characteristics and response.
Median age at first MMC infusion (years) 56 (26 - 86)
Median number of MMC cycles per patient 3 (1 - 11)
Median dose of MMC (mg) 12 (6-12)
Median number of cycles before response assessment 2 (1-5)
Response after MMC (n=132)
 Partial response 26 (14.8%)
 Stabile disease 76 (43.2%)
 Progressive disease 30 (17%)
No response assessment possible 44 (25%)
Adverse Events
In table 3, all clinical and biochemical adverse events in 176 patients with a 
total of 599 MMC infusions are listed. Thrombocytopenia was the most often 
occurring adverse event. No grade 5 adverse events occurred after MMC 
infusion. Two patients developed an adverse event concerning the kidney. The 
first patient developed chronic kidney failure after the sixth cycle of MMC. This 
patient had a mono kidney and ended with permanent peritoneal dialysis (grade 
4). The second patient developed a thrombotic microangiopathy after the sixth 
cycle of MMC which was treated with steroids (grade 2). A second grade 4 
adverse event occurred and consisted of a thrombocytopenia below 25 10**9/L 
which was treated by 2 packages of platelets. The fact that methyl prednisolone 
was also prescribe could have contributed to the thrombocytopenia.
A sepsis was seen in one patient after the second MMC infusion that was 
treated with systemic antibiotic treatment. One patient developed an acalculous 
cholecystitis that was treated with laparoscopic cholecystectomy. Eight patients 
experienced a haematoma at the puncture site. An allergic reaction to the 
contrast agent appeared in 5 patients during the procedure, of which one had 
to be treated with intravenous medication (grade 3).
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Table 3. Adverse events after MMC infusion.
Adverse events (n=176)  Grade 1 Grade 2 Grade 3 Grade 4
Clinical n (%)
 Fatigue 55 (31 %) 4 (2 %) 0 0
 Pain 62 (35 %) 2 (1 %) 3 (2 %) 0
 Nausea 54 (31 %) 2 (1 %) 1 (0.5 %) 0
 Emesis 15 (8 %) 0 0 0
 Weight loss 8 (5 %) 2 (1 %) 0 0
 Gastrointestinal ulcer 0 1 (0.5%) 0 0
 Allergic reaction 3 (2 %) 2 (1 %) 1 (0.5%) 0
 Hematoma at injection site 7 (4%) 1 (0.5%) 0 0
 Sepsis 0 0 1 (0.5%) 0
 Kidney disease 0 2 (1%) 0 1 (0.5%)
 Other 35 (20%) 2 (1%) 1 (0.5%) 0
Biochemical n (%)
 Leukopenia 53 (30 %) 12 (7 %) 2 (1 %) 0
 Thrombocytopenia 96 (55 %) 22 (13 %) 6 (3 %) 1 (0.5 %)
 Anaemia 43 (24 %) 10 (6 %) 0 0
 Increased aspartate aminotransferase 30 (17 %) 7 (4 %) 3 (2 %) 0
 Increased alanine aminotransferase 24 (14 %) 4 (2 %) 1 (0.5 %) 0
 Increased bilirubin 8 (5 %) 6 (3 %) 8 (5 %) 0
 Increased alkaline phosphatase 11 (6 %) 4 (2 %) 1 (0.5 %) 0
 Increased gamma-glut amyl transferase 22 (13 %) 3 (2 %) 1 (0.5 %) 0
 Decrease in estimated glomerular 
filtration rate
5 (3%) 0 0 0
Response by RECIST
Post procedural CT for response assessment was available in 132 (75%) of 
the patients. Median time to RECIST response assessment was after 2 cycles 
of MMC infusion (range 1-5). Response rate in the liver after MMC consisted 
of PR (n=26, 14.8%)(figure I), SD (n=76, 43.2%) and PD (n=30, 17%). In 44 
patients (25%) no response assessment was obtained.
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Figure 1. Hepatic response before (A) and after (B) 2 cycles of MMC
Figure 2. Kaplan Meier curve overall survival by three groups; responders (PR + SD); 
non-responders (PD) and patients with no response assessment (NR). Median OS was 
11.9 months for the responders, 4.2 months for the non-responders and 1.7 months for 
the patients with no response assessment
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Survival analysis
At time of analysis 3 patients were still alive; the other 173 patients had died. 
Median OS was 7.8 months (95% CI of 6.1-9.8). In fi gure II an overview is shown 
of the OS outlined in diff erent groups (disease control (PR+SD), progressive 
disease (PD), no response assessment (NK)), a global test showed a signifi cant 
diff erence between the three groups (p<.0001). Median survival for patients 
that obtained disease control was 11.9 months (CI 10-16.1) and 4.2 months (CI 
2.8-6.9) for patients that showed PD (p<0.0001). In patients where no response 
assessment (NR) was not obtained median survival was 1.7 months (1.3-2.4 
months). Median hPFS in the 107 patients in which radiological follow up was 
available was 5.5 months (CI=4.5-6.8) as shown in fi gure III.
Figure 3. Kaplan Meier curve of hepatic progression free survival (hPFS) by RECIST. 
Median hPFS was 5.5 months
Factors infl uencing overall survival
Univariable analysis of the association of pre-treatment characteristics with 
overall survival is presented in table 1. Multivariable analysis (table 4) showed 
that a higher number of previous lines of systemic chemotherapy (HR=1.2; 
CI=1.1-1.3), a higher tumour burden (>50%) (HR=2.4; CI=1.5-3.7), prior ablation 
of the liver (HR=5.9 CI=1.8-19.4) and elevated levels of bilirubin (HR=2.18; 
CI=1.3-3.8) and alanine transaminase (ALT) (HR=1.5; CI=1.01-2.09) were 
independently associated with a worse OS. After the addition of response 
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assessment by RECIST to the previously chosen multivariable model, PD by 
RECIST was significantly associated with a worse OS (PD vs PR; HR=3.98 
CI=2.3-7.02 p<0.0001).
Table 4. Multivariable model of factors influencing overall survival.
Variable Test N (%) Hazard Ratio (95% CI) P-value
Systemic 
chemotherapy lines 
before MMC
Linear trend: 
+1 unit
167 (95%) 1.166 (1.080;1.259) <.0001
Prior liver ablation None 173 (98%) Ref Ref
Performed 3 (2%) 5.938 (1.818;19.395) 0.0032
Tumour burden liver Global test <.0001
< 25 % 85 (50%) Ref Ref
25-50 % 44 (26%) 2.050 (1.391;3.022) 0.0003
> 50 % 41 (24%) 2.384 (1.534;3.706) 0.0001
Baseline bilirubin level Not elevated 153 (88%) Ref Ref
Elevated 21 (12%) 2.183 (1.265;3.767) 0.0050
Baseline ALT level Not elevated 58 (34%) Ref Ref
Elevated 115 (66%) 1.457 (1.016;2.089) 0.0406
ALT: alanine aminotransferase, HR: hazard ratio, CI: confidence interval
Continuous variables/linear trend: HR>(<)1: higher (lower) risk for higher predictor level
Categorical variables: global p-value for any difference between groups
Binary variables pairwise tests: HR>(<)1: higher (lower) risk for given category 
compared to reference
DISCUSSION
In this study we demonstrated that MMC infusion was safe and effective in 
a cohort of 176 heavily pre-treated LMBC patients with a total of 599 MMC 
infusions. Multivariable analysis showed that an increased number of prior 
systemic chemotherapeutic lines, a higher tumour burden of the liver, prior 
ablation of the liver and elevated baseline levels of bilirubin and ALT, were 
independently associated with a worse OS.
Progression or resistance to systemic chemotherapy often occurs in the LMBC 
patients, which is associated with a worse survival [16]. To overcome this 
resistance, local intra-arterial therapies may offer high local concentrations 
of chemotherapy in the liver with low toxicity providing a break from systemic 
chemotherapy [10, 17]. Literature about MMC infusion in LMBC patients is very 
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limited. Prior research demonstrated the safety of MMC in a smaller cohort 
of 30 patients [14]. In the present study of a large cohort, we confirmed that 
intra-arterial MMC infusion was safe with only 17.5% patients with a grade 3 or 
higher adverse events despite a heavily pre-treated metastatic breast cancer 
(MBC) population. These toxicity levels are low compared to other therapies 
for resistant metastatic breast cancer patients, such as Eribulin that has a 30% 
grade 4 adverse event and overall 99% adverse events [18, 19]. Ideally, intra-
arterial MMC should be tested in a randomized phase III study compared to 
systemic therapy of physician’s choice, but it is unlikely that such a study will 
ever happen.
A known severe systemic side effect of MMC administration is HUS [12, 13]. In 
the present study two patients had a side effect concerning the kidney, however 
no HUS occurred in a total of 599 intra-arterial MMC infusions. Therefore, we 
conclude that MMC can be safely used by intra-arterial infusion.
In this study we observed a median OS of 7.8 months. In the literature, other 
groups have reported a median OS of 7 months [20], 14 months [21], 13.2 
months [22], 11.4 months [23] after MMC infusion [20], MMC with Folic acid 
plus 5-Fluorouracil [21], and MMC plus Gemcitabine [22, 23], respectively. 
These differences can be explained by the differences in disease extension 
and amount of prior therapy received before intra-arterial infusion. The rather 
low OS rate in our cohort certainly reflects the advanced stage of MBC 
where patients had a median of 4 prior systemic treatments for metastatic 
disease before starting MMC and a 36.6 months interval between diagnosis 
of metastases and MMC infusion.
It may be important to select patients for MMC infusion that can have the most 
benefit of the treatment. For that reason, we performed a multivariable analysis 
of independent pre-treatment factors associated with OS. The independent 
factors associated with a poor survival were all related to extensive prior 
treatment and high tumour load in the liver accompanied with deteriorated 
laboratory liver tests. In the literature, previously reported factors for worse 
overall survival in LMBC patients were administration of previous therapy, 
higher number of metastatic locations and baseline liver dysfunction which is 
in line with our findings [24-27]. Patients that responded, by RECIST, to the 
therapy had a significantly longer OS, compared to patients that had PD or 
when no response assessment was possible. The very short OS of the patients 
without response assessment (1.4 months) shows that these patients probably 
did not responded to the therapy. Therefore, this early endpoint is useful to 
evaluate if continuation of the therapy is justified. This is rather opposite to 
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response assessment in patients treated with systemic chemotherapy where 
a literature based analysis of 24 trials reported only a moderate association 
between objective response rate and OS in patients treated with 2nd and 3th 
line chemotherapies [28].
Besides chemo infusion, other intra-arterial therapies are available for 
LMBC patients consisting of transarterial chemo embolization (TACE) and 
radioembolization (TARE) [10]. Inclusion criteria for TARE and TACE are more 
strict, compared to chemo infusion, resulting in less advanced diseased LMBC 
patients with longer median overall survival (6.6-13.6 and 4.6-47 months, 
respectively) [29-31]. For TACE, all grade adverse events are reported up to 
71% of the patients with grade 3 ≥ adverse events in 34.7% of the patients [32, 
33]. TARE is generally better tolerated than TACE, with adverse events grades 
around 44% [32]. Response rates whereby disease control is obtained after 
TARE and TACE differ widely from 52-99% and 40-83%, respectively [29-31].
Limitation of our study is the retrospective nature of this study, namely the 
retrospective assessment of the patient records for toxicity and response 
assessment. Next to that, response assessment was only possible in 132 of 
the 176 patients and assessment of hPFS was only possible in 107 of the 176 
patients. Further, patients were included over a period of 17 years in a rapidly 
changing therapeutic landscape.
In conclusion, intra-arterial MMC infusion was able to obtain disease control in 
58% of the LMBC patients (PR and SD) with a low toxicity profile. MV analysis 
showed a worse OS in patients with an increased amount of prior therapies, 
a higher liver tumour burden and elevated levels of bilirubin and ALT. Further 
prospective studies are needed to determine the exact place of intra-arterial 
MMC infusion and other intra-arterial therapies in LMBC patients.
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ABSTRACT
Purpose: The aim of the study was to evaluate the safety and feasibility of 
intra-arterial Mitomycin C (MMC) infusion after selective internal radiation 
therapy (SIRT) using yttrium-90 (90Y) resin microspheres in liver metastatic 
breast cancer (LMBC) patients.
Patients and Methods: This prospective pilot study included LMBC patients 
from 2012-2018. Patients first received infusion of 90Y resin microspheres, after 
6-8 weeks response to treatment was assessed by MRI, 18F-FDG PET/CT and 
laboratory tests. After exclusion of progressive disease, MMC infusion was 
administrated 8 weeks later in different dose cohorts; A: 6mg in 1 cycle, B: 12 
mg in 2 cycles, C: 24 mg in 2 cycles and D: maximum of 72 mg in 6 cycles. In 
cohort D the response was evaluated after every 2 cycles and continued after 
exclusion of progressive disease. Adverse events (AE) were reported according 
to CTCAE version 5.0.
Results: Sixteen patients received 90Y treatment. Four patients were excluded 
for MMC infusion, because of extra hepatic disease progression (n=3) and 
clinical and biochemical instability (n=1). That resulted in the following number 
of patient per cohort; A:2 B:1 C:3 and D:6. In 4 of the 12 patients (all cohort 
D) the maximum dose of MMC was adjusted due biochemical toxicities (n=2) 
and progressive disease (n=2). One grade 3 AE occurred after 90Y treatment 
consisting of a gastrointestinal ulcer whereby prolonged hospitalization was 
needed.
Conclusion: Sequential treatment of intra-arterial infusion of MMC after 90Y 
SIRT was feasible in 75% of the patients when MMC is administrated in different 
escalating dose cohorts. However, caution is needed to prevent reflux after 90Y 
SIRT in LMBC patients.
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INTRODUCTION
Up to 50 percent of the metastatic breast cancer (mBC) patients eventually 
develop liver metastases which is associated with a poor overall survival 
ranging from 1-3 years [1, 2]. Liver metastatic breast cancer (LMBC) patients 
with limited (extra) hepatic disease can obtain a survival benefit from local 
treatment options, such as surgery and ablation [3, 4]. Unfortunately, most 
LMBC patients have extended disease whereby systemic treatment by 
chemotherapy or anti-hormonal therapy, in hormone sensitive breast cancer, 
is indicated. Systemic treatment with chemotherapy has lengthened overall 
survival, but haematological, gastrointestinal and neurotoxicity are dose-limiting 
factors with systemic administration of these agents [5]. Therapies with less 
systemic toxicity are therefore an attractive treatment option in LMBC patients 
refractory to systemic chemotherapy [6].
Several intra-arterial therapies have been applied for LMBC patients, such as 
radioembolization (yttrium-90 (90Y) resin microspheres), chemo embolization 
and chemo infusion, reported as effective and safe treatment options 
[7-9]. Of these treatments, the best results are reported for intra-arterial 
radioembolization, with a disease control rate of 72-91% and an overall survival 
of 6.6 – 13.6 months [7, 10-12]. For over 15 years, LMBC patients are treated by 
intra-arterial chemo infusion with Mitomycin C (MMC) in our institute whereby 
disease control is obtained in 58% with low adverse events in a very heavily 
pre-treated cohort [9].
Since primary breast cancer is sensitive for both systemic chemotherapy and 
external beam radiation therapy, LMBC patients might also benefit from the 
combined treatment of chemo infusion and selective internal radiation therapy 
(SIRT). However, the sequential administration of these intra-arterial therapies 
e.g. SIRT and intra-arterial chemo infusion, has not yet been reported. In this 
pilot study we prospectively analysed the safety and feasibility of the sequential 
intra-arterial infusion of 90Y resin microspheres and MMC in patients refractory 
to conventional systemic chemotherapy.
MATERIAL AND METHODS
This prospective phase I pilot study of 16 patients was approved by the ethics 
committee of our hospital (S 53657). Patients were included from April 2012 
until March 2018. All patients signed a written informed consent. Patient 
selection was performed by a multidisciplinary tumour board consisting of 
4
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medical, surgical and radiation oncologists together with pathologists, nuclear 
medicine physicians and (interventional) radiologists.
In table 1, the inclusion and exclusion criteria for this pilot study are shown. 
Figure 1 shows the treatment schedule of 90Y SIRT followed by MMC infusion 
in the different cohorts. The first 3 patients were allocated to cohort A, the 
second 3 patients to cohort B, the 3 patients thereafter to cohort C and the 
remaining of the patients in cohort D. Patients first underwent the 90Y treatment 
and in the absence of progression, the sequential intra-arterial hepatic MMC 
infusions were administrated 8 weeks later.
Table 1. Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Histologically confirmed diagnosis of 
breast cancer
Bilirubin level >1.5x upper limit normal
Radiological evidence of liver 
metastases
Transaminase (AST/ALT) >2.5x upper 
limit normal
Liver only or liver predominant with 
stable extra-hepatic disease
Creatinine >1.2x upper limit normal
Progressive under (multi-line) systemic 
chemo or hormonal therapy
Glomerular filtration rate <60 mL/
min/1.73m2
Eligible for intra-arterial therapy Neutrophils <1000/µL
Age >18 years Thrombocytes <100 x109/L
Karnofsky performance >70 Lung shunt fraction >20%
Allergy to contrast media
Active use of oral anticoagulation
AST = Aspartate Aminotransferase; ALT = Alanine aminotransferase
Radioembolization with yttrium-90 (90Y) resin microspheres
All 90Y procedures were performed under local anaesthesia by or under 
direct supervision of an expert interventional radiologist (GM) and nuclear 
medicine physician (CD). Previously published work describes the details 
of the 90Y treatment [13]. Briefly, patients first underwent a detailed baseline 
angiogram and embolization of enterohepatic arteries with micro-coils 
according to the expertise of the interventional radiologist. Technetium-99m 
-macroaggregated albumin (99mTC-MAA) was injected in the target vessels 
and a planar scintigraphy was performed to determine the lung shunt fraction. 
Two weeks later patients underwent bilobar or unilobar injection of 90Y resin 
microspheres (SIR spheres®, Sirtex Inc, Cosgrove, Australia) under local 
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anaesthesia. The activity of 90Y injected in the patient was calculated based 
on the body surface area method. In patients where it was possible to use 
the partition model, the partition model was used instead of the body surface 
area method. Dependent on the site of lesions, the 90Y resin microspheres 
were injected intra-arterially via a micro catheter to the right and left liver lobe 
(superselective). A Progreat® micro catheter (Terumo, Europe) or an anti-reflux 
catheter (Surefire Inc., Westminster, CO, USA) was used for injection of the 
microspheres. Patients received antiemetics and morphine derivates before 
90Y injection when required.
Figure 1. Treatment overview of the 16 patients treated with selective internal radiation 
therapy with Yttrium-90 containing microspheres (90Y SIRT) and mitomycin C (MMC) 
infusion in 4 escalating cohorts. 
a Due to extra hepatic disease progression
b Due to the biochemical and clinical toxicities
Hepatic intra-arterial chemo infusion with MMC
Six to eight weeks after the 90Y treatment, patients underwent response 
assessment by magnetic resonance imaging (MRI) of the liver and a whole 
body [18F]-FDG positron emission tomography/computed tomography 
scan (18F-FDG PET/CT) together with laboratory tests. If patients showed 
no untreatable progression of disease on MRI and 18F-FDG PET-CT scan 
(bases on RECIST criteria 1.1) together with acceptable laboratory results (> 
100*109 thrombocytes/L), the intra-arterial chemo-infusion of MMC could be 
4
BrigitAarts_BNW.indd   61 08/09/2020   14:27:52
62
Chapter 4
administrated. Six to ten weeks after the 90Y procedure, patients received the 
first infusion of MMC, as previously described by our group [14]. After local 
anaesthesia, vascular access was obtained by the right common femoral artery 
and, using a diagnostic 4-French catheter, a micro catheter was placed in the 
right and left hepatic arteries for injection of MMC in both liver lobes.
Ascending maximal doses of MMC were administrated in different cohorts. 
Patients were allocated to the MMC cohort before the 90Y procedure. The first 
cohort (A) received one cycle of 6mg MMC, the second cohort (B) received 
one cycle of 12mg MMC, the third cohort (C) received 2 cycles of 12mg of 
MMC and the fourth cohort (D) received the standard regime of MMC infusion 
consisting of a maximum of 6 cycles of each 12mg of MMC. Before and after 
the MMC infusion laboratory results were taken to determine whether the 
dose could be tolerated. The dose of MMC was adjusted when thrombocyte 
count was <100*109 thrombocytes/L. In the last cohort, the effect of MMC 
was radiologically evaluated, by CT or MRI, after every two cycles. If these 
evaluations showed no further intra- or extra-hepatic disease progression, 
the patient was rescheduled for the next 2 cycles for a maximum of 6 cycles.
Outcomes
The primary outcomes of this study included the feasibility and safety of MMC 
infusion after 90Y SIRT. The feasibility was defined as the number of patients 
receiving the MMC infusion after 90Y treatment. The safety was determined by 
the number of grade 3 and higher adverse events after MMC and 90Y treatment 
and documented by the Common Terminology Criteria for Adverse Events 
version 5.0. For the response assessment the modified response evaluation 
criteria in solid tumours (mRECIST) was used to measure hepatic response 
by a maximum of two target lesions and categorized into four categories 
[Complete Response (CR), Partial Response (PR), Stable Disease (SD) and 
Progressive Disease (PD)] [15].
Statistical analysis
Patient and pre-treatment characteristics were presented as numbers, 
percentages and median time with range. Overall survival (OS) was calculated 
from work-up for 90Y treatment until death or loss to follow up by the Kaplan 
Meier estimates. All analyses were performed in SPSS (IBM Corp, version 
25, Armonk, NY).
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RESULTS
Patient characteristics
Table 2 shows the patient characteristics of the 16 treated women. The median 
time from diagnosis of metastatic breast cancer to start of the study was 28 
months (range 7.7 – 91 months). Patients were 26 - 77 (median 59) years old 
at the start of the study. A liver biopsy was taken before start of the study in 
15 patients and showed a positive oestrogen receptor in 8 patients, positive 
progesterone receptor in 8 patients and a negative HER2-neu status in all 
patients (n=15). Six patients had a triple negative receptor status. Tumour 
burden of the liver was <25% in 9 patients and >25% in 7 patients. Nine patients 
had extra-hepatic disease with a median of 1 site (range 0-4) and bone (n=5) 
as most common site. Before inclusion, the median number of chemotherapy 
lines in the metastatic phase was 3 regimes consisting of anthracyclines in 
75% and taxanes in 81%.
Treatment
Figure 1 shows a treatment overview of the 16 patients. All 16 patients 
underwent the 90Y procedure whereby pre-embolization of extra hepatic 
arteries was performed in 14/16 patients. A median doses of 1.68 GBq (range 
1.043 – 2.140) was inserted in both liver lobes (n=14) or one liver lobe (n=2). At 
response evaluation five patients showed extra-hepatic disease progression, 
of whom, three patients were excluded for additional MMC infusion and two 
patient received the sequential MMC infusion, but with additional therapy of 
Exemestane (Aromasin®) for stabilization of their extra-hepatic disease. One 
patient was hospitalized after 90Y SIRT for 2.5 weeks because of the side 
effects of the 90Y treatment and excluded from further treatment.
Median time between 90Y SIRT and first MMC infusion was 2.1 months (range 
1.7 - 12.8 months). In one patient an interval of 12.8 months occurred, because 
of PD in the liver after 90Y treatment. This patient first received systemic 
chemotherapy and after progression during this systemic chemotherapy the 
MMC infusion was administrated. A total of 12 patients were treated in four 
different cohorts of MMC doses after the 90Y treatment (Figure 1). In cohort D, 
the maximum of 6 cycles of 12 mg MMC was administrated in 2 patients. In the 
other four patients the dose was adjusted (n=2) and discontinued (n=2) due to 
hematologic toxicity (thrombocytopenia) and disease progression.
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Table 2. Patient Characteristics
Patient Characteristics N = 16
Median months from diagnosis metastatic disease until start of study 28 (8-91)
Median age at start study in years (range) 59 (26-77)
Diagnosis of liver metastasis
 Synchronous 2 (12.5%)
 Metachronous 14 (87.5%)
Hormone status of liver metastasis (n=15)
 Estrogen receptor (positive) 8 (53%)
 Progesterone receptor (positive) 8 (53%)
 HER2Neu receptor (negative) 15 (100%)
 Triple negative receptor status 6 (40%)
Tumor burden liver
 < 25% 9 (56%)
 25%-50% 6 (38%)
 50%-75%  1 (6%)
Prior hepatic treatment
 Surgery/Ablation 1 (6.3%)
Median number of chemotherapy regimens for stage 4 disease 3 (0-8)
Extra-hepatic sites of metastases
 Yes 9 (56%)
 No 7 (44%)
Number of additional metastatic sites
 1 5 (31%)
 2 2 (13%)
 ≥3 2 (13%)
Location of extrahepatic metastases
 Bone 5 (31%)
 Lung 3 (19%)
 Non-locoregional nodes 4 (25%)
 Brain 2 (13%)
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Table 3. Number of grade 1 (G1), grade 2 (G2) and grade 3 (G3) adverse events after 
treatment of selective internal radiation therapy by 90Y labelled microspheres infusion 
(90Y SIRT) and Mitomycin C (MMC) infusion within 30 days. No grade 3 adverse events 
occurred after MMC infusion.
Treatment 90Y SIRT MMC
Cohort A
1x6mg
MMC
Cohort B
1x12mg
MMC
Cohort C
2x12 mg
MMC
Cohort D
max 
6x12mg
Adverse events G1 G2 G3 G1 G2 G1 G2 G1 G2 G1 G2
Clinical
 Fatigue 2/16 - - - - - - 3/3 - 2/6 -
 Pain 5/16 2/16 - - - - - - - 1/6 -
 Nausea 3/16 2/16 - - - - - - - 1/6 -
 Emesis 2/16 2/16 - - - - - - - 1/6 -
 Gastrointestinal ulcer - 4/16 1/16 - - - - - - - -
Biochemical
 Leukopenia 2/16 - - - - - - 2/3 - 4/6 2/6
 Thrombocytopenia 3/16 1/16 - 1/2 - 1/1 - 3/3 - 4/6 2/6
 Anaemia - - - - - - - - - 4/6 -
 Increased aspartate 
aminotransferase 5/16 1/16
- - - - - - - 2/6 -
 Increased alanine 
aminotransferase 3/16 1/16
- - - - - - - 1/6 -
 Increased bilirubin - - - - - - - 1/3 1/3 - -
 Increased alkaline 
phosphatase 2/16 1/16
- - - - - 1/3 - 2/6 -
 Decreased eGFR - 1/16 - - - - - - - - -
 Increased gamma-
glutamyl transferase 4/16 1/16
- - - - - 1/3 - 4/6 -
eGFR = estimated glomerular filtration rate
Adverse events
Table 3 shows the adverse events after the 90Y SIRT and MMC infusion. After 
the 90Y treatment one grade 3 adverse event occurred, consisted of a gastric 
ulcer treated with proton pump inhibitors and hospitalization. The most common 
grade 1/2 adverse events after 90Y SIRT were pain 7/16, nausea 5/16 and ulcer 
4/16. An elevation in liver function test (aspartate, alanine and gamma-glutamyl 
transferase) was seen in 8/16 patients. No grade 3 or higher adverse events 
occurred after MMC infusion. The most common grade 1/2 adverse event was 
thrombocytopenia in 11/12 patients and leukopenia in 8/12 patients.
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Response
Response evaluation of the liver after 6 to 8 weeks after 90Y treatment (n=16) 
revealed PR in 10 patients and SD in 6 patients (Figure 2). Extra hepatic 
response evaluation showed PD in 5 patients and SD in 11 patients. Additional 
hepatic response of MMC infusion after 90Y treatment was PR in 4/12 patient, 
SD in 5/12 patients and PD in 3/12 patients.
Follow-up and survival
After the study, nine patients were eligible to receive systemic chemotherapy 
and one patient was eligible for surgery and underwent a segmentectomy. The 
median OS was 12.6 months (95% CI 10.23-15.0).
Figure 2. Hepatic response on magnetic resonance imaging (MRI) before 90Y treat-
ment (A), after 90Y treatment (B) and after 2 cycles of MMC infusion (C). C is a partial 
response relative to A. Arrows indicate the liver metastases.
DISCUSSION
Intra-arterial therapy is a treatment option in patients with chemo-refractory 
liver dominant metastatic breast cancer [6]. In our institute MMC infusions are 
performed for almost 20 years for chemo refractory LMBC whereby a disease 
control of 58% is obtained with low grade adverse events [9]. In the present 
study we investigated whether MMC infusion is feasible and safe after 90Y SIRT.
The sequential treatment of 90Y followed by MMC was possible in 75% (12/16) 
of the enrolled patients. Only low grade adverse events (grade 1 and 2) were 
observed after the MMC infusions. In addition, the gradual escalation of the 
MMC infusions, ranging from 6 mg in 1 cycle to a maximum of 72 mg in 6 
cycles, caused no additional adverse events.
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During the regular MMC protocol of our institute, patients can receive a 
maximum of 72 mg in 6 cycles whereby close monitoring is performed to adjust, 
postpone or stop the MMC infusion after each cycle [9]. In current study, the 
same protocol was followed in the last cohort, subsequently 4 patients did not 
receive all 6 MMC cycles. Thus, this pilot shows that the regular protocol of 
MMC can be followed after prior treatment with 90Y. Patients maintained their 
performance status after the sequential treatments, and so 9/12 patients were 
eligible for systemic therapy afterwards and 1/12 even for hepatic surgery. 
Therefore, this combination treatment can be used as a drug holiday from 
systemic treatment.
We did observe a high amount of gastrointestinal ulcers after 90Y SIRT (n=5, 
31%). All these patients underwent pre-embolization and received a bilobar 
treatment in the left and right hepatic artery. Despite these precautions, the 
ulcers occurred probably due to reflux and non-target deposition of the 90Y 
resin microspheres which is a known risk of 90Y treatment for LMBC [16]. 
After the introduction of an anti-reflux catheter in the last 6 patients, no more 
ulcers occurred. According to the literature, several factors are associated with 
reflux of 90Y resulting in gastrointestinal ulcering, namely prior administration 
of monoclonal antibodies (i.e. bevacuzimab, trastuzumab), the type of 90Y 
microspheres and the dose of 90Y. [10, 17]. In the present study no correlations 
were found for prior monoclonal antibodies treatment and the dose of 90Y 
with the development of gastrointestinal ulcers. The development of the 
gastrointestinal ulcers in the current study was probably caused by several 
pre-treatment and treatment related factors. The use of the anti-reflux catheter 
showed improvement with no further reported gastrointestinal ulceration. 
Therefore, caution is definitely needed in future studies.
The median OS of radioembolization in LMBC patients ranges from 6.6 – 13.6 
months, which is in line with the median OS of 12.6 in this study [10,11, 18-20]. 
The median OS was higher compared to earlier studies where patients received 
only MMC infusion (12.6 versus 7.6 months) [9, 14]. However, the inclusion 
criteria for this study were more strict than our routine indications for MMC 
infusion. Consequently, patients had less extensive local and extra hepatic 
disease with a better performance status compared to our previous reported 
cohort of patients treated with MMC infusion only.
The main limitation of this study consists of small patient number in the cohorts 
and the long inclusion period.
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In conclusion, the sequential treatment of intra-arterial infusion of MMC after 
90Y therapy is feasible with limited low grade adverse events after MMC. The 
regular MMC protocol can be followed with adjustment of MMC dose based on 
clinical, radiological and biochemical parameters. However, caution is needed 
to prevent reflux after 90Y SIRT in LMBC patients. Further research is needed to 
show whether the combination of 90Y and MMC has a benefit over the treatment 
of MMC or 90Y alone in LMBC patients.
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ABSTRACT
Purpose: To assess the difference between renal mass biopsy (RMB) 
performed either before or during the ablation procedure.
Methods: A retrospective multi-center study was performed in patients with 
a cT1 renal mass treated with ablation between January 2007 and July 2019, 
including a search in the national pathology database for patients with a RMB 
planned for ablation. Patient and tumor characteristics and information on 
malignant, benign and non-diagnostic biopsy results were collected to establish 
rates of overtreatment and number of ablations avoided in case of benign or 
non-diagnostic histology.
Results: RMB was performed in 714 patients, of which 231 patients received 
biopsy before planned ablation, and 483 patients at the time of ablation. 
Pathology results before ablation were malignant in 63% (145/231), benign 
in 20% (46/231) and non-diagnostic in 17% (40/231). Pathology results at the 
time of ablation were malignant in 67.5% (326/483), benign in 16.8% (81/483) 
and non-diagnostic in 15.7% (76/483), leading to a total of 32.5% of ablation of 
benign or non-diagnostic lesions. Of the patients with a benign biopsy obtained 
before ablation, 80.4% (37/46) chose not to undergo ablation. Patients with 
inconclusive biopsy before planned ablation, chose an informed individualized 
approach including ablation, repeated biopsy or no intervention in 56%, 34% 
and 10%.
Conclusion: This study emphasizes the importance of obtaining a biopsy prior 
to the ablation procedure in a separate session to lower the rate of potentially 
unnecessary ablations.
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INTRODUCTION
Renal cell carcinoma (RCC) accounts for 2-3% of all malignancies worldwide 
and is the tenth most common tumor in both males and females in western 
countries [1,2]. The incidence of small localized RCC lesions (<4 cm) has 
dramatically increased in the last decade due to the expansion of imaging 
modalities. Standard treatment for small renal masses (SRMs) is a partial 
nephrectomy [3], but in comorbid or elderly patients, a more minimal invasive 
treatment can be preferred, such as focal thermal ablation or active surveillance 
or stereotactic radiotherapy [4,5].
Although some renal masses show malignant characteristics on radiological 
images, up to 30% are found to be benign after (partial) nephrectomy [6,7]. 
Renal mass biopsy (RMB) can be performed to differentiate between a 
malignant or benign renal tumor. The renal cancer guideline of the European 
Association of Urology (EAU) recommends to perform a percutaneous RMB 
before the ablation procedure [4]. However, in clinical practice different 
strategies are applied with biopsies performed either before the ablation in a 
separate session or at the time of the ablation procedure itself.
The reason for performing a biopsy at the time of ablation is regularly to 
allow both procedures to be performed in one session. The disadvantage 
of this strategy is overtreatment or uncertainty regarding follow-up in case 
pathological assessment or remains non-diagnostic [8,9].
This study aims to evaluate the differences between RMB performed before or 
at the time of ablation in terms of histological diagnosis and rate of treatment 
of benign tumors and uncertainty.
METHODS
Patient selection
This multi-center retrospective study was conducted in the Renal Cancer 
Network Amsterdam, consisting of the OLVG hospital, the Netherlands Cancer 
Institute (NKI), and Amsterdam University Medical Center (AUMC). The study 
had appropriate institutional review board approval from each institution. A 
data transfer agreement was obtained to execute a pooled data analyses of 
the three centers together.
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Patients treated by ablation for a renal tumor between January 2007 – July 
2019 were included. Furthermore, the PALGA database, the nationwide network 
and registry of histo- and cytopathology in the Netherlands, was searched 
for patients who were diagnosed by means of an RMB in the three centers 
mentioned above and were not treated due to either a benign or non-diagnostic 
biopsy result. All patients were discussed in a multidisciplinary tumor board 
consisting of urologists, medical oncologists and (interventional) radiologists 
and these reports were retrospectively evaluated. If the board decided that the 
patient was not intended to be treated with an ablation, the patient was excluded 
from this study. Consequently, patients planned for (partial) nephrectomy or 
with a renal infection or abscess were excluded. If the board advised a patient 
to be treated with an ablation, the patient would be included.
Only primary tumors limited to the kidney and smaller than seven centimeter 
were included (cT1 tumors). Patients were excluded from the study in case of 
prior surgery or ablation of the kidney or intrarenal metastases from another 
primary malignancy.
Renal masses were diagnosed by a board of certified abdominal radiologists 
on multiphase computed tomography. An RCC was suspected when a 
hypervascular mass was found on contrast-enhanced CT. Lesions were 
considered suspicious for malignancy when an increase of at least 15 
Hounsfields units after contrast administration was observed. When a suspected 
lesion was found on US, a multiphase CT with an arterial, corticomedullary and 
nephrogenic phase was performed. From 2017 onwards, all patients (treated 
and non-treated) were discussed in a multicenter multidisciplinary tumor 
board between the three centers during a weekly video conference meeting. 
Patients with a tumor ≤4 cm (cT1a) were offered the choice between surgical 
and ablative procedures or active surveillance, unless patient comorbidity 
supported a specific choice. Ablation for tumors >4 cm and ≤7cm (cT1b) was 
only offered for highly comorbid patients who were not eligible for surgery. All 
procedures were performed or supervised by an experienced, board certified, 
interventional radiologist.
Biopsy before the ablation procedure
Biopsies before the ablation were taken in a separate session from the ablation 
procedure. RMB was guided by ultrasound (US) or computed – tomography 
(CT) under local anesthesia. Different biopsy needles were used in each 
hospital (Center 1: Argon Medical 18G, Center 2: co-axial Bard® Magnum® 
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18G, Center 3: Cook 16 G or 18G). After the biopsy procedure, patients were 
given two hours bed rest with monitoring of vital signs.
Biopsy at the time of ablation
Biopsies were taken in the same session as the ablation procedure, 
immediately before the start of the thermal ablation. The ablation procedure 
was performed by US and/or (cone beam) CT guidance under local or general 
anesthesia depending on the patient, tumor characteristics and preference of 
the physician. Different ablation techniques, such as radio frequency ablation, 
micro wave ablation, laparoscopic and percutaneous cryoablation were used 
in the three hospitals.
Pathologic evaluation
Histological assessment was performed at each hospital according to the 
EAU guidelines by an experienced genitourinary pathologist. The Union 
for International Cancer Control/American Joint Committee on Cancer 
classification was used when an RCC was diagnosed by the pathologist [4]. 
Results were regarded as diagnostic if the tissue sample was either defined 
as definitively benign or malignant or if a preference for a diagnosis was made 
by the pathologist. Biopsies were considered non-diagnostic if the biopsy 
tissue only contained normal parenchyma, fibrosis, necrosis or was not 
representative. In case of an oncocytic neoplasma in which no differentiation 
between a benign or malignant oncocytic lesions could be performed, the 
lesion was classified as “no diagnosis” (Table 2). For the pathological analysis, 
the specific staining protocol for the suspicion of renal neoplasms was followed. 
Those stains included cytokeratins, vimentin, cadherins, RCC Marker and other 
RCC-specific markers. The analyses were performed by a board certified 
urogenitary pathologist.
Data analysis
Patient and radiologic tumor characteristics and pathology results were 
collected to establish rates of diagnostic accuracy, overtreatment and avoided 
ablation in case of benign histology. Patients were divided into two groups: 
those receiving a biopsy before a planned ablation, and those receiving a 
biopsy during the ablation procedure (see Figure 1). Adverse events after the 
biopsy were classified according to the Clavien-Dindo classification [10].
Continuous variables are shown as median with interquartile range and 
categorical variables as numbers and percentages. Differences between 
groups were calculated by the Chi-square method for the categorical data and 
5
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an independent t-test and Mann Whitney U test for the numerical variables. 
All tests were two-sided and p-values below 0.05 were considered statistically 
significant. Statistical analysis was conducted with SPSS V.25 (IBM Corp, 
Armonk, NY, USA).
Figure 1. Flow chart of the biopsies performed before or at the ablation.
RESULTS
Pretreatment characteristics
A total of 1070 patients were scheduled for thermal ablation in the three 
hospitals between January 2007 and July 2019. Of these, 356 patients did 
not meet the inclusion criteria and were excluded, in the majority of the cases 
because they received treatment without a biopsy, multiple ablations in the 
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same patient (whereby only the first ablation was taken into account), treatment 
of tissue other than the kidney or prior history of renal surgery, leaving 714 
patients for analysis (Figure 1 and table 1).
Table 1. Patient characteristics
Patient 
characteristics
Total group 
(n=714)
Biopsy performed 
in a separate 
session before 
the ablation 
procedure (n=231)
Biopsy performed 
in same session 
as the ablation 
procedure (n=483)
p
Median age (IQR) 69 (61-75) 68 (59-74) 70 (62-76) 0.070
Gender
 Male. n (%) 448 (62.7%) 152 (65.8%) 296 (61.3%) 0.250
 Female. n (%) 266 (37.3%) 79 (34.2%) 187 (38.7%) 0.250
Significance was assumed for p<0.05
Biopsy before planned ablation in a separate session
231 patients underwent a biopsy in a separate session before the ablation. 
Pathology results after the first biopsy were malignant in 60.2% (139/231), 
benign in 18.2% (42/231) and non-diagnostic in 21.6% (50/231).
In the benign group, 33/42 patients (78.5%) were not treated as a result of the 
benign pathology result. Nine patients in this group wished to be treated. Of 
the 50 patients in the non-diagnostic group, 28 chose ablation. In 17 patients, a 
second biopsy was performed, resulting in six malignant biopsies (all treated), 
four benign biopsies (all not treated) and seven non-diagnostic biopsies (three 
treated). Altogether, a total of 37 patients (80% of the benign tumors) chose not 
to undergo a planned ablation, due to a benign biopsy result.
After the second biopsy, the final pathology results before ablation were 
malignant in 63% (145/231), benign in 20% (46/231) and non-diagnostic in 17% 
(40/231). In the group of 40 patients who had a non-diagnostic result after a 
second biopsy, 32 opted for treatment and 8 were not treated with an ablation 
for personal reasons (see Figure 1). Histological results of these biopsies are 
shown in table 2.
Biopsy during the ablation procedure
In 483 patients, a biopsy was only performed during the ablation procedure, 
without having information about the histology of the tumor prior to ablation. The 
5
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decision to perform an ablation was based upon high suspicion of malignancy 
on imaging. In this group, 81 (16.8%) benign tumors were treated, 76 (15.7%) 
tumors with a non-diagnostic pathology result and 326 (67.5%) malignant 
tumors. Together, 157 patients (32.5%) with a proven benign or non-diagnostic 
lesion were treated.
Potential overtreatment
In the group receiving a biopsy before a planned ablation, 80.5% of the biopsies 
resulted in an ablation procedure, compared to 100% in the group receiving 
only a biopsy during ablation. In the group only receiving a biopsy during the 
ablation procedure, overtreatment might have occurred in 32.5% of all ablations 
due to a benign or non-diagnostic biopsy result, compared to 17.7% in the 
group undergoing a biopsy before planned ablation and who chose for ablation 
despite being informed about the result (p<0.001). There were no significant 
differences in age, gender or tumor size between the groups of patients who 
received a biopsy in a separate session before the ablation and the group who 
received a biopsy at the time of ablation.
Adverse events
Adverse events related to the renal biopsy were reported in 3 of the 714 patients 
(0.4%), all of which occurred in the patients who underwent the biopsy in a 
separate session before the ablation. One patient (0.14%) developed a grade 3a 
adverse event after a biopsy before ablation (histological result: oncocytoma) 
consisting of a false aneurysm which was treated with embolization. The other 
two adverse events were grade 1, both being patients who did not feel well after 
the procedure and had to be observed in the hospital, with no further medical 
or interventional measures taken.
DISCUSSION
Percutaneous biopsies performed in experienced centers have a high diagnostic 
yield, specificity and sensitivity and low morbidity [11]. In this multi-center study 
we evaluated the implications for treatment decisions and follow-up of biopsies 
performed before ablation in a separate session or during ablation. We showed 
that performing a biopsy during the ablation procedure led to 16.8% benign 
and 15.7% non-diagnostic biopsies, suggesting a potentially unnecessary 
ablation of renal masses in 32.5%. In addition, 19.5% of the patients who were 
diagnosed with a benign or non-diagnostic biopsy result decided not to undergo 
their planned ablation. A total of 37 patients (80% of the benign tumors) chose 
not to undergo a planned ablation, due to a benign biopsy result. Performing 
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a biopsy before ablation therefore reduces overtreatment and allows patients 
and physicians to adjust clinical management according to the biopsy results.
In this cohort, biopsies performed during the ablation procedure led to an 
ablation of a histologically confirmed benign tumor in 16.8% of the patients. 
Although, that is just marginally higher than previous reports of ablation series 
(ranging from 2 – 14%), it is in line with the rates reported after surgery of 
small renal masses without previous biopsy (up to 30%)[7,12,13]. Results from 
our retrospective analysis demonstrate that patients who were involved in the 
choice of management after a benign biopsy result, chose to not undergo 
the ablation in the majority of the cases (80%) and therefore avoided an 
unnecessary treatment.
Performing a biopsy during the ablation procedure eliminates the possibility to 
perform an additional biopsy and creates uncertainty for follow-up in case of an 
inconclusive biopsy. In our cohort, 15.7% of the patients who received a biopsy 
in the same session as the ablation procedure had a non-diagnostic biopsy. 
Physicians therefore had to consider that the renal mass was malignant and 
followed an intensive follow-up scheme of multiple CT or MRI scans. Contrast 
enhanced imaging, necessary for detection of recurrence after ablation, can 
be a burden in patients with chronic kidney disease including most patients 
planned for ablation and, in case of CT scans, expose patients to radiation. 
In case a non-diagnostic biopsy could be repeated and confirmed as benign, 
a less intensive follow-up scheme of active surveillance would have been 
followed. In the literature, this is reported in up to 33% of the beforehand 
suspected malignant renal masses after partial nephrectomy. [8,9].
Taking a renal mass biopsy (RMB) in a separate session has additional 
advantages. First, Tsang Mui Chung et al suggested that for percutaneous 
image guided ablations, an RMB can inform the interventional radiologist about 
the actual ablation procedure regarding patient position and percutaneous 
approach in case the same image guided modality is used [14]. Second, clinical 
impact can be achieved according to histologic subtype before treatment.
On the other hand, performance of a biopsy during the ablation avoids the 
need for another hospital visit. Several patients chose to undergo an ablation 
regardless of the benign histological result, in our cohort 19.5%. Reasons for 
this were, for example, that patients still preferred a treatment and, in case of 
an angiomyolipoma, to lower the risk for bleeding [15,16]. Also, the risk of a 
biopsy can be substantial in high risk patients on anticoagulation that cannot 
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be paused. In our cohort only one biopsy required an intervention. Physicians 
need to discuss the different histological results and their consequences with 
the patient in a shared decision process including the need for a biopsy.
In literature, only two other groups investigated the timing of the biopsy in 
patients undergoing ablation. Wells et al., recommend to perform a biopsy 
before the ablation in a separate session with the opportunity to take a second 
biopsy during the ablation. However, they only included patients who underwent 
ablation and consequently did not report changes of clinical management due 
to a benign biopsy before treatment [6]. Tsang Mui Chung et al. concluded that 
a biopsy during the ablation did not lead to overtreatment, because only 3% 
of the ablated lesions were benign. However, they included oncocytoma as 
not definitively benign in their analysis, which consequently lowered the rate 
of benign renal masses [13]. Differentiation between oncocytomas and low 
grade oncocytic neoplasms is difficult, since, as reported in literature, up to 
35% of the oncocytomas by means of biopsy receives a different histological 
diagnosis after surgical resection [17]. In the present study we therefore 
classified oncocytic lesions that were not strictly marked as an oncocytoma 
as “no diagnosis”, instead of an oncocytoma, and only used oncocytoma when 
this was strictly classified as such by the pathologist. In our study, we found 6 
cases where the pathologist could not further specify the oncocytic lesion, and 
we have therefore included those in the “no diagnosis” group.
As with all retrospective studies, one of the main limitations of our study is that 
it is subject to bias, in particular selection bias. In this study no randomization 
was performed which resulted in a relatively small number of biopsies 
performed before the ablation in a separate session. Our results, however, 
seem to contradict this management and propagate performing the biopsy 
before planned ablation to avoid unnecessary treatment of benign lesions and 
uncertainty of follow-up of inconclusive lesions.
CONCLUSION
This study emphasizes the importance of obtaining a biopsy prior to the ablation 
procedure in a separate session to lower the rate of unnecessary ablations.
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ABSTRACT
Objectives: To assess the safety and efficacy of percutaneous microwave 
ablation (MWA) of histologically proven T1 Renal Cell Carcinoma (RCC).
Methods: We analysed patients with a histologically proven RCC (≤7 cm) 
treated by MWA from April 2012 - April 2018. Primary and secondary efficacy, 
local tumour recurrence (LTR), morbidity and mortality were reported. Efficacy 
was defined as no residual tumour enhancement on follow-up imaging one 
month after the first ablation (primary efficacy) and after re-ablation(s) for 
residual disease (secondary efficacy). Adverse events (AE) were registered 
by the Clavien Dindo classification and the common terminology criteria for 
AE. Univariable and multivariable logistic regression analyses were performed 
to investigate a relation among pre-treatment factors incomplete ablation and 
complications.
Results: In 100 patients a total of 108 RCC’s (85 T1a and 23 T1b) were treated 
by MWA. Median size was 3.2 cm (IQR 2.4-4.0). Primary efficacy was 89% 
(95%CI 0.81-0.94) for T1a lesions and 52% (95%CI 0.31-0.73) for T1b lesions 
(p<0.001). 15 lesions (7 T1a) were re-ablated for residual disease by MWA in 
one (n=13) and two (n=2, T1b) sessions resulting in secondary efficacy rates 
of 99% (T1a) and 95% (T1b, p=0.352). LTR occurred in four tumours (2 T1a, 
2 T1b) after 10-60 months. Six (4%) AE’s grade >3-5 were observed (2 T1a, 4 
T1b, p=0.045). Multivariable analysis showed that mR.E.N.A.L. nephrometry 
was independently associated with incomplete ablation (p=0.012).
Conclusion: Microwave ablation is safe and effective for T1a and T1b RCC 
lesions with a significantly lower primary efficacy for T1b lesions.
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INTRODUCTION
Renal cell carcinoma (RCC) accounts for 3% of all cancers worldwide[29]. 
According to the European Association of Urology (EAU) and the National 
Comprehensive Cancer Network (NCCN) RCC guidelines, partial nephrectomy 
(PN) is the gold standard for T1a RCC. Percutaneous tumour ablation is 
reserved for co-morbid patients and patients not eligible for surgery[20; 24]. 
Although reports show higher local control after PN compared to ablative 
therapies, similar cancer-specific survival is obtained with less renal function 
decline for radiofrequency ablation (RFA) and cryoablation (CA)[31].
Details of the different ablation modalities, RFA, MWA and CA, are extensively 
described in the literature. To summarize, MWA, compared to RFA, achieves 
higher temperatures in a shorter time less influenced by the heat sink effect. 
As a result a fast and large ablation zone with a similar applicator as RFA is 
achieved.[4; 19] With RFA and MWA, the evolvement of the ablation zone 
during the procedure is less visible compared to CA[15]. Reports about the 
efficacy and safety of large cohorts of MWA remain limited, especially for T1b 
tumours[8; 9].
In this retrospective cohort study, we report the outcomes of patients with a 
histologically proven RCC treated by means of MWA in a tertiary reference 
centre. The purpose of this study was to evaluate the safety, efficacy and 
factors influencing outcome of MWA in T1a and T1b RCC.
PATIENTS AND METHODS
Study population
The institutional review board of our hospital approved this retrospective study 
(IRBd18059). The data of all MWA’s of our institute was requested through 
our institutes data desk and consent of all patients was checked. We included 
patients treated by MWA for a histologically proven T1 RCC between April 2012 
and April 2018. Patients were excluded when prior therapy (chemotherapy, 
surgical resection or a different ablation modality) for RCC was administrated.
MWA procedure
All patients were first discussed in a multidisciplinary tumour board, consisting 
of urologists, radiologists and medical oncologists to decide patients eligibility 
for MWA. The MW procedures were performed computed tomography (CT) 
guided (CT Somatom Sensation Open, Siemens®, Munchen, Germany). 
6
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Patients were treated with two different MW systems (2012-2014: Evident® 
MW system (Covidien®, Dublin, Ireland), 2014-2018: Emprint® MW system 
(Medtronic®, Dublin, Ireland)). Dissection was performed with 5% glucose 
solution plus 10% iodinated contrast, CO2 and room air for tumours adjacent 
to vulnerable structures. Ureteric perfusion with cooled saline was used for 
tumours close to the collection system and the proximal ureter. Antenna 
placement was performed with CT fluoroscopy and optimal position verified by 
CT before start of the ablation. After antenna placement biopsy was performed. 
In principle, a power of 100 watt was used for 2-10 min according to tumour 
size. A margin of 5 – 10 mm was attempted to achieve complete ablation. 
Fluoroscopic CT check was performed to monitor the procedure. In larger 
tumours, the ablation was repeated with different antenna positions to achieve 
a complete ablation zone. With the Evident® MW system, multiple antennas 
were placed in the tumour according to physicians choice.
Follow-up
An institutional follow-up scheme of multiphase CT scans after 1, 3, 6, 9 and 12 
months was executed. Patients with a diminished renal function were followed 
by (non-)contrast enhanced magnetic resonance imaging (Achieva or Ingenia, 
Philips Healthcare®, Best, the Netherlands). According to agreement with our 
in house urologists follow-up for the first year was performed by the IR at our 
outpatient clinics. When no recurrence appeared patients were send back to 
the referring urologist. A follow-up scheme of 1 multiphase CT scan a year for 
5 years was advised to the referring urologist.
Data collection and statistical analysis
Tumour characteristics were scored according to the R.E.N.A.L. nephrometry 
score (Radius, Exophytic/endophytic, Nearness to collecting system or sinus 
and Location relative to polar lines) and modified (m)R.E.N.A.L. nephrometry 
score, as published previously [25]. Adverse events (AE’s) during ablation were 
registered by the common terminology criteria for adverse events (CTCAE) and 
post ablation AE’s were registered following the Clavien Dindo classification. 
Primary efficacy was defined as no residual tumour enhancement visible at post 
contrast CT or MRI one month post ablation. Secondary efficacy was described 
as the percentage of tumours successfully treated for residual disease by 
repeated MWA(s)[1]. Patients treated with another secondary treatment 
modality (i.e. PN, radical nephrectomy (RN), RFA or CA) were excluded for 
the secondary efficacy. Local tumour recurrence (LTR) was defined when new 
enhancement within a successfully treated ablation zone occurred during the 
follow-up.
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Continuous variables are shown as median and interquartile ranges (IQR) 
and categorical data as numbers and percentages. To test differences 
between categories, the Chi-square or Fisher exact test was used and for 
non-parametric continuous variables the Mann-Witney test. To analyse the 
relationship between pre-treatment factors with incomplete ablations and the 
occurrence of complications, a logistic regression analysis was performed. 
Results are presented as odds ratio (OR), 95% confidence interval (CI) and 
significance levels. For the multivariable logistic regression analysis, only 
significant variables from the univariable analysis were included. Significance 
levels of p<0.05 were used. Analyses were performed using Statistical Package 
for the Social Sciences (SPSS, version 25, Chicago, IL).
RESULTS
Patient and tumour characteristics
Between April 2012 - April 2018, 226 patients underwent a MWA for their renal 
masses. 126 patients were excluded because of non-diagnostic biopsy (n=55), 
benign biopsy (n=30), treatment for recurrence disease after prior treatment 
(n=12), metastatic disease (n=23), T3 disease (n=2), tumour debulking (n=2), 
prior chemotherapy for tumour reduction (n=1) and no follow-up imaging 
available after the MWA (n=1). 100 patients with 108 histologically proven 
RCC were included in this analysis, patient and tumour characteristics are 
shown in table 1.
Table 1. Pretreatment characteristics
All
(n=108)
T1a
(n=85)
T1b
(n=23)
P value
Number of patients 100 77 23
Median age at treatment, IQR 71 (63-77) 69 (63-76) 74 (63-77) 0.2851
Male 59 (59%) 48 (62%) 11 (48%) 0.2352
History
 Cardiovascular 30 (30%) 21 (25%) 9 (39%) 0.3062
 Oncological 38 (38%) 29 (38%) 9 (39%) 0.8992
 Urological 22 (22%) 15 (19%) 7 (30%) 0.3892
Median size, IQR 3.2 (2.4-4.0) 2.8 (2.2-3.5) 4.5 (4.3-5.0) 0.0001
Laterally 0.3572
 Right 56 (52%) 42 (49%) 14 (61%)
 Left 52 (48%) 43 (51%) 9 (39%)
6
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Table 1. Continued.
All
(n=108)
T1a
(n=85)
T1b
(n=23)
P value
Aetiology tumour 0.0962
 Clear cell 68 (63%) 51 (60%) 17 (74%)
 Papillary 22 (20%) 21 (25%) 1 (4%)
   Type I 14 14 0
   Type II 4 3 1
 Chromophobe 4 (4%) 4 (5%) 0
 Eosinophilic 1 (1%) 0 1 (4%)
 Undefined renal cell carcinoma 13 (12%) 9 (11%) 4 (17%)
Fuhrman grade 0.5012
 1 23 (21%) 17 (20%) 6 (26%)
 2 32 (30%) 23 (27%) 9 (39%)
 3 6 (6%) 5 (6%) 1 (4%)
 Undefined/ Not possible 47 (44%) 40 (47%) 7 (31%)
Location 0.1752
 Exophytic 61 (57%) 44 (52%) 17 (74%)
 < 50% exophytic 11 (10%) 10 (12%) 1 (4%)
 Endophytic 36 (33%) 31 (36%) 5 (22%)
 Anterior 26 (24%) 23 (27%) 3 (13%) 0.0762
 Posterior 62 (57%) 44 (52%) 18 (78%)
 Mid 20 (19%) 18 (21%) 2 (9%)
 Lower pole 31 (29%) 25 (29%) 6 (26%) 0.8742
 Upper pole 35 (32%) 28 (33%) 10 (43%)
 Inter pole 42 (39%) 32 (38%) 7 (30%)
Distance to collecting system 0.0042
 >7 mm 66 (61%) 58 (68%) 8 (35%)
 4-7 mm 11 (10%) 9 (11%) 2 (9%)
 <4mm 31 (29%) 18 (21%) 13 (57%)
Distance to polar lines 0.1552
 Entirely above/ below 62 (57%) 52 (61%) 10 (43%)
 Lesion crosses 1 polar line 27 (25%) 21 (25%) 6 (22%)
 >50 % of mass across polar line 19 (18%) 12 (14%) 7 (35%)
R.E.N.A.L. nephrometry score 6 (4-8) 5 (4-7) 7 (6-9) 0.0001
 Low (4-6) 68 (63%) 60 (71%) 8 (35%) 0.0022
 Intermediate (7-9) 28 (26%) 17 (20%) 12 (52%) 0.0072
 High (10-12) 12 (11%) 8 (9%) 4 (18%) 0.2802
m.R.E.N.A.L. nephrometry score 6 (5-9) 5 (4-8) 8 (7-10) 0.0001
 Low (4-6) 59 (55%) 55 (65%) 4 (17%) 0.0002
 Intermediate (7-9) 29 (27%) 19 (23%) 10 (44%) 0.0622
 High (10-12) 20 (19%) 11 (13%) 9 (40%) 0.0041
1 = mann-witney test 2=chi square, IQR = Interquartile range
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Primary and secondary efficacy
A total of 125 MW ablations were performed in 108 tumours. The Evident® 
MW system was used in 14 MWA’s with the use of multiple antennas (2-3) 
in 10 tumours. The Emprint® MW system was used in the other 111 MWA’s. 
Dissection was used in 37% of the procedures with five ureter perfusions. 
Patients were mostly placed in the CT scanner in a prone position (75%), under 
epidural (98%) or general (2%) anaesthesia. Primary efficacy was achieved in 
88 lesions (81%) (table 2, figure 1a-c). T1a lesions had a significantly higher 
primary efficacy (89%; CI 0.81-0.94) compared to T1b lesions (52%; CI 0.31-
0.73) (p<0.001). 15 tumours (53% T1b) received a second MWA and two 
T1b tumours a third MWA. Secondary efficacy of MWA was reached in 97% 
(101/103) (all tumours), 99% (82/83) (T1a) and 95% (19/20) (T1b, p=0.352). Five 
tumours (5/20, 2 T1a and 3T1b) were not re-treated by MWA and excluded for 
the secondary efficacy, but were all successfully treated by means of surgery 
(PN; T1a) and other ablative techniques (RFA (1 T1a tumour (1x re-RFA) and 
1 T1b tumour (3x re-RFA)), CA (n=1; T1b)) and no treatment (patients choice). 
In five lesions the second MWA was incomplete (1 T1a, 4 T1b) and were 
successfully treated with MWA (n=2). In three lesions another ablative modality 
was used (CA (n=2) and RFA (n=1)).
Table 2. Efficacy for T1a and T1b RCC lesions.
All T1a T1b P value
Primary efficacy 88/108 (81%) 76/85 (89%) 12/23 (52%) <0.001
Remnant 20/108 (19%) 9/85 (11%) 11/23 (48%) <0.001
Secondary efficacy 101/103 (98%) 82/83 (99%) 19/20 (95%) 0.352
Recurrence 3/105 (3%) 1/83 (1%) 2/22 (9%) 0.110
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Figure 1. a-c: Microwave ablation (MWA) of a T1b tumour (A) before MWA (B) during 
MWA (C) one year after MWA: complete ablation. d-f: endophytic T1a lesion with a 
close relation to the collecting system (D). (E+F): 9 months after complete ablation, 
hydronephrosis of the kidney visible due to an urinary tract stenosis that occurred 3 
months after the MWA (kidney function from 45 ml/min/1.73m2 to 19 ml/min/1.73m2) 
(NB this patients is familiar with liver cysts).
Adverse events
A total of 24 (19%) AE’s were observed after the 125 MWA procedures 
including six major AE’s (4%) with a significantly higher number of major AE’s 
in T1b tumours (2 T1a -2%- and 4T1b -13%-, p=0.045)(table 3). There was no 
significant difference in the occurrence of all complications and T stage (18 
T1a -20%- and 6 T1b -18%-, p=1.000). One major AE consisted of an active 
bleeding on the control scan during the MWA, which was successfully coiled 
embolized (CTCAE grade 3). One patient died 13 days after the ablation due 
to cardiac and renal failure (Clavien-Dindo grade 5). In two patients, an urinary 
tract stenosis arose after the MWA (Clavien-Dindo 4a) after 1 and 2 months 
resulting in a non-functional kidney (see figure 1d-f). In three patients, a urinary 
tract stenosis occurred 1, 2 and 5 months after the MWA without loss of renal 
function (Clavien-Dindo 1). All five lesions were endophytic T1a lesions, with 
a close relation to the collection system (4 lesions < 4 mm, 1 lesions 4-7 mm). 
Cooling of the urinary tract system was performed in one lesion. One patient 
with macroscopic haematuria required transfusion with packed red blood cells 
and antibiotics (both grade 3). Nineteen (15%) minor AE’s occurred (Clavien 
Dindo grade 1+2).
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Table 3. Adverse events during and post ablation.
Gradea n T stage
During ablation
 Tumour bleeding required embolization 3 1 T1b
Post ablation
 Dead within 30 days 5 1 T1b
 Urinary tract stenosis with renal function loss 4a 2 T1a
 Ureteral blood loss required endoscopic intervention 3 2 T1b
 Infection treated with antibiotics 2 2 T1a,b
 Urinary tract stenosis (without renal function loss) 1 3 T1a
 Self-limiting (peri-renal or liver) bleeding 1 4 T1a,b
 Pneumothorax 1 3 T1a
 Sensibility loss of skin 1 1 T1a
 Pain 1 2 T1a
 Nausea 1 2 T1a,b
  Skin burnb 1 1 T1a
a according to the Common terminology criteria for adverse events during ablation 
and according to the Clavien-Dindo Classification post ablation.
b The skin burn occurred at the antenna insertion and was successfully treated with 
silver sulfadiazine cream.
Factors influencing outcome
R.E.N.A.L. nephrometry score (OR 1.56, p=0.001), mR.E.N.A.L. nephrometry 
score (OR 1.58, p=0.000) and tumour aetiology (clear cell vs non clear cell 
OR 0.11, p=0.034) were significantly associated with an incomplete ablation, 
however, only mR.E.N.A.L. nephrometry score remained significantly 
associated in the multivariable regression analysis (OR=3.854 p=0.012) 
(table 4). Of the mR.E.N.A.L nephrometry score, size (>3 and >4), nearness 
to the collecting system (<4mm) and distance to the polar lines (score 3) were 
significantly associated with an incomplete ablation.
6
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Table 4. Pretreatment factors and their association with an incomplete ablation and 
the occurrence of complications after microwave ablation of T1 renal cell carcioma.
Univariable Multivariable
Variable Test OR 95% 
CI
P 
value
OR 95% 
CI
P 
value
Incomplete ablation
 Tumour aetiology Clear cell vs non 
clear cell
0.107 0.01-0.85 0.034 0.077 0.04-
1.3
0.077
 Fuhrman gradec Grade 1 vs grade 2+3 1.286 0.4-4.3 0.688 - - -
Grade 1 vs unknown 0.429 0.1-1.7 0.221 - - -
 Age Continue 1.005 0.96-1.06 0.833 - - -
 Gender Male vs Female 0.770 0.3-2.1 0.600 - - -
 History Cardiovascular Yes vs no 0.714 0.2-2.2 0.551 - - -
 History Oncological Yes vs no 0.492 0.2-1.3 0.157 - - -
 History Urological Yes vs no 0.882 0.3-2.7 0.882 - - -
 Tumour location Left vs right 1.500 0.6-4.0 0.421 - - -
Anterior vs Posterior 0.391 0.08-1.9 0.242 - - -
Anterior vs Inter 0.720 0.2-2.4 0.589 - - -
 System Emprint vs Evident 0.342 0.1-1.2 0.086 - - -
 R.E.N.A.L. nephrometry 
score
Continue 1.559 1.2-2.0 0.001 0.356 0.1-1.1 0.069
 mR.E.N.A.L. nephrometry 
score
Continue 1.577 1.2-2.0 0.000 3.854 1.3-11 0.012
Complications
 Age Continue 0.994 0.95-1.0 0.772 - - -
 Gender Male vs Female 1.063 0.4-2.6 0.895 - - -
 History Cardiovascular Yes vs no 0.729 0.3-2.0 0.542 - - -
 History Oncological Yes vs no 0.941 0.4-2.3 0.895 - - -
 History Urological Yes vs no 1.234 0.4-3.6 0.704 - - -
 Tumour location Left vs right 1.346 0.6-3.3 0.517 - - -
Anterior vs Posterior 0.682 0.3-2.0 0.521 - - -
Anterior vs Inter 0.692 0.2-2.7 0.598 - - -
 Dissection Yes vs no 1.091 0.4-2.8 0.856 - - -
 System Emprint vs Evident 1.314 0.3-5.2 0.697 - - -
 R.E.N.A.L. nephrometry 
score
Continue 1.308 1.1-1.6 0.013 - - -
 mR.E.N.A.L. nephrometry 
score
Continue 1.226 1.1-1.5 0.016 - - -
a In the univariable analysis all variables were analyzed to determine the relation of 
(m)R.E.N.A.L. nephrometry score and their components with incomplete ablation 
and complication.
b In het multivariable analysis only the significant variables from the univariable 
factors were used.
 c Fuhrman grade is a nuclear grading system of clear cell RCC that evaluated the 
nuclear size, shape and nucleolar prominence
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Univariable analysis showed that only R.E.N.A.L. nephrometry score (OR 
1.308, p=0.013) and mR.E.N.AL nephrometry score (OR 1.577, p=0.016) were 
associated with the occurrence of complications. Of the (m)RENAL score only 
the nearness to the collecting system (<4mm) was significantly associated with 
the occurrence of complications.
Follow-up
Median follow-up time was 19 months (IQR 12-35 months; min-max 0-78 
months, 90 patients (90%) 1 year follow up available). During this period four 
(4%) tumours showed LTR (2 T1a and 2 T1b tumours) after 10, 13, 26 and 60 
months. One tumours was successfully treated by MWA and two recurrences 
by another modality (CA). One of the recurrences has not been treated yet. One 
patient treated by MWA for bilateral chromophobe RCC tumours, developed 
a new lesion in the same kidney for which he underwent active surveillance. 
Five patients (4 T1a tumours, 1 T1b tumours) developed metastases of which 
two were histologically proven RCC. During follow-up no patient died of RCC.
DISCUSSION
Percutaneous ablation is considered as treatment option in co-morbid patients 
with a T1 RCC tumour not eligible for PN [20; 24]. RFA and CA are widely 
applied and established ablation techniques that are included in guidelines 
contrary to MWA which has still limited supportive data [20; 24; 26].
In this study, we show the result of 108 RCC’s treated with MWA. There was 
a significantly higher primary efficacy for T1a tumours (89%) compared to 
T1b tumours (52%). In the 125 performed MWA’s, 19% AE’s were observed, 
mostly low grade (15%), with a significantly higher number of major AE’s in T1b 
tumours (13% T1b vs 2 % T1a, p=0.045). The R.E.N.A.L. and mR.E.N.A.L. 
nephrometry score were related to incomplete first ablation and the occurrence 
of complications. The factors, size (>3 cm and >4 cm), nearness to the collecting 
system (<4mm) and distance to the polar lines (score 3) of the mR.E.N.A.L 
nephrometry score were associated with incomplete ablation and nearness to 
the collecting system (<4mm) for the occurrence of complications.
For all primary MWAs, a primary efficacy of 81% was observed with a primary 
efficacy of 89% for T1a tumours. After repeated MWA(s) a secondary efficacy 
of 99% was reached for T1a tumours. In the literature primary efficacy rates of 
MWA from 84.6-100% are reported[7; 10; 13; 21; 28]. Therefore, the primary 
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and secondary efficacy of T1a tumours underpins the existing evidence 
supporting MWA for the treatment of T1a RCC lesions .
The primary efficacy of T1b tumours (52%) was significantly lower compared 
to T1a tumours (p<0.001). In 48% of the T1b lesions a second or third ablation 
was performed to achieve a complete tumour ablation resulting in a secondary 
efficacy of 95%. In the literature, lower efficacy rates of percutaneous ablation 
are described for tumours over 4 cm [28] which is in line with our findings. We 
shows that repeated MW ablations can achieve high efficacy rates even in large 
tumours. Besides the tumour size, our cohort contained difficult tumours with 
a close relation to the collecting system. Reports of percutaneous ablation of 
T1b RCCs by MWA are rare and series are small[3; 8]. Primary efficacy rates 
between 75% and 100% were reported in 12 and 7 T1b tumours, respectively[11; 
32]. In the literature, CA is more commonly used as ablation technique for T1b 
lesions with primary efficacy rates ranging from 76% to 97.2%[2; 5; 12; 14]. 
Our results show that MWA can also be used and chosen as a treatment 
modality in T1b tumours with consideration of a second ablation. Future cost-
effectiveness studies have to show the exact place of the difference ablation 
techniques for RCC.
The overall AE rate of 19% was relatively high compared to previous 
percutaneous ablation and surgical studies[8; 31]. However, most AE’s were 
low grade (15%) with minimal consequences for the patient. In our series we 
found a significant difference between T1a and T1b tumour for the occurrence 
of major AE’s. Five patients had a stenosis of the urinary tract, 1-5 months 
after MWA that resulted in renal function loss in two patients. Nearness to the 
collecting system was significantly associated with incomplete ablation and 
complications. Therefore, we suggest caution during MWA treatment for lesions 
close to the collecting system. In the literature, 13 cases of injury to the urinary 
tract system after MWA are reported[6; 10; 18; 22; 30; 32]. Klapperich et. al 
observed 6 asymptomatic urinomas that resulted in renal cortex volume loss 
in 3 patients[18]. Preclinical work on a histologically level shows damage of 
MWA to the collecting system by direct puncture of the collecting system and 
heating of the urine during the ablation[23; 27]. Damage to the gastrointestinal 
tract was reported by others, but not observed in the current study[15; 17].
Multivariable analysis showed an independent association of the mR.E.N.A.L. 
nephrometry score for an incomplete first ablation. In addition, univariable 
analysis shows a relation of R.E.N.A.L. and m.R.E.N.A.L. nephrometry score 
with the occurrence of complications. This is in line with Ierardi et al. that also 
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reported an association of the (m)RENAL nephrometry score with incomplete 
ablation and complications after MWA [16] and Camacho et al. that first 
described this association after RFA and cryoablation [6]. Other groups did 
not find this association. To specify, Klapperich et al. only found an association 
between local recurrence after MWA and tumour histology characteristic, and 
not between the R.E.N.A.L. score and local recurrence [18]. Shakeri et al. 
observed a significantly higher median tumour size in lesions that required a 
second MWA, but no association with tumour location and R.E.N.A.L score[28]. 
Also, Wells and et al. did not found an association with the RENAL score and 
treatment outcome [32]. These reports are all opposite to our findings which 
may suggest that MWA is not as straight forward as previously reported.
The LTR in this study was 4% over a 108 histologically proven RCC’s. In the 
literature LTR ranges from 0-17%[6; 11; 28], but most papers included every 
renal lesions without excluding non-diagnostic or benign lesions whereby 
efficacy and recurrence rates might be overestimated [22; 30; 32]. Surprisingly, 
the time to LTR was long in this current cohort which could be explained by 
the difficulties in detecting of recurrences in hypo vascular tumours and slow 
growth rates of low grade tumours.
Limitations of this study include a single centre retrospective study whereby 
details of the MW procedure were not complete with the lack of in house long-
term follow up (>1year) in some patients. Ideally we would describe a larger 
cohort, but the peri-operative biopsy strategy resulted in some non-diagnostic 
and benign lesions.
In conclusion, primary efficacy of MWA in T1a tumours was significantly higher 
compared to T1b tumours. Repeated ablation was necessary in 19% achieving 
efficacy rates of 95% (T1a) and 99% (T1b). Low grade AE’s were seen after 
MWA whereby close monitoring of the urinary tract is recommended following 
ablation of tumours adjacent to the urinary tract. Incomplete ablation was more 
often seen in lesions with a larger size with a close relation to the collecting 
system and the polar lines accompanied expressed in a higher mR.E.N.A.L. 
nephrometry score. Prospective data have to determine the exact position of 
MWA for the treatment of RCC.
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ABSTRACT
Cancer cells can escape the immune system by different mechanisms. The 
evasion of cancer cells from immune surveillance is prevented by immune 
checkpoint inhibitors, allowing the patient’s own immune system to attack 
their cancer. Immune checkpoint inhibitors have shown improvement in overall 
survival for melanoma, lung cancer and renal cell carcinoma in clinical trials. 
Unfortunately, not all patients respond to this therapy. In cancer management, 
percutaneous ablation techniques are well established for both cure and local 
control of many tumour types. Cryoablation of the tumour tissue results in cell 
destruction by freezing. Contrary to heat based ablative modalities, cryoablation 
induces tumour cell death by osmosis and necrosis. It is hypothesized that with 
necrosis, the intracellular contents of the cancer cells stay intact allowing the 
immune system to induce an immune-specific reaction. This immune-specific 
reaction can, in theory, also affect cancer cells outside the ablated tissue, 
known as the abscopal effect. Unfortunately, this effect is rarely observed, 
but when cryoablation is combined with immunotherapy, the effect of both 
therapies may be enhanced. Although several preclinical studies demonstrated 
a synergistic effect between cryoablation and immunotherapy, prospective 
clinical trials are needed to prove this clinical benefit for patients. In this review, 
we will outline the current evidence for the combination of cryoablation with 
immunotherapy to treat cancer.
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INTRODUCTION
Cryoablation is a percutaneous ablation technique that uses extreme low 
temperatures for tumour destruction [1]. During cryoablation liquefied gas, such 
as nitrogen or argon, is passed through cryoprobes and expands into a gaseous 
state at the end of the probe to create temperatures as low as − 190 °C. Cytotoxic 
cell destruction is achieved at temperatures below − 20 °C. To ensure complete 
ablation of the tumour, a circumferential margin of 1 cm is needed [2]. After 
the freezing phase, a thawing phase follows by replacing the liquefied gas with 
helium or internally heating the needle (available in new systems). The whole 
process of freezing-thawing is repeated to obtain an effective ablation. Intra-
procedure computed tomography (CT) identifies the ablated zone in real time as 
a low-density area which corresponds to the generated ice ball (Fig. 1).
Figure 1. Cryoablation of a patient with stage IA renal cell carcinoma. The hypodense 
area around the needle corresponds with the generated ice ball in real time.
The procedure results in focal destruction of tumour tissue in a minimal invasive 
setting with reduced morbidity and mortality and represents a cost-effective 
alternative to surgery [3, 4]. However, surgery remains the gold standard in 
most tumour types with additional pathological assessment of margins [5, 6]. 
A possible advantage of cryoablation is that the intracellular contents of the 
damaged tumour cells are preserved and can be recognised by the immune 
system initiating a tumour-specific immune response (Fig. 2) [7, 8].
Recently, immune checkpoint inhibitors have been studied for treatment of 
melanoma, renal cell carcinoma (RCC) and non-small lung cancer (NSLC). 
The challenge of the immune checkpoint inhibitors is that only a minority of 
patients respond. Therefore, a combination treatment of cryoablation and 
immunotherapy, might be beneficial to enhance the effect of the immune 
checkpoint inhibitors (Fig. 3). In the early 1970s, Shulman et al. reported the 
production of antibodies specifically against cryoablated tissue in rabbits 
[9, 10]. This immunogenic effect potentially resulted in a “bystander effect” 
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with regression of tumours outside the primary ablation zone, known as the 
abscopal effect, firstly defined by Mole after radiotherapy [11, 12]. Unfortunately, 
this effect occurs infrequently, but when cryoablation is combined with other 
immunomodulatory therapy, this effect might be enhanced (Fig. 3) [13]. Here, 
we review the current evidence on the combination of cryoablation with 
immunomodulatory drugs (immunotherapy).
Figure 2. One of the hypotheses of how cryoablation induces an immune response 
is in the way cell death is induced. Cryoablation induces cell death by both necrosis 
and apoptosis. Necrosis releases intra-cellular contents stimulating signals (among 
others danger signals) that may activate T cells for a specific immune response to the 
cryoablated tissue. Contrary, after cell death by apoptosis, only apoptotic bodies are 
released, without stimulating signals. Without these stimulating signals, T cells are 
not being activated. Therefore, apoptosis may lead to an immune-suppressing signal.
Figure 3 For T cell activation, both stimulatory signal 1 and 2 are needed. Signal 1 
consists of the interaction between the major histocompatibility complex on the den-
dritic cell and the T cell receptor. Different combinations of interactions are possible for 
signal 2. One inhibiting signal 2 is the interaction between programmed death receptor 
1 (PD-1) on T cell and programmed death ligand 1 (PD-L1) on tumour cells or antigen 
presenting cells. a T cell activation is blocked by an inhibiting signal 2 between PD-L1 
and PD-1 receptor binding. b When an anti-PD1 antibody is used, the inhibiting signal 
of the T cell is blocked whereby an activation signal of the T cell is gathered and the 
T cell is activated.
BrigitAarts_BNW.indd   120 08/09/2020   14:28:01
121
Cryoablation and immunotherapy
MATERIAL AND METHOD
A literature search in MEDLINE was performed for available publications between 
2001 and 2017 about cryoablation, its effect on the immune system and the 
combination of cryoablation and immunotherapy. Only full text articles available 
in English were included. Keywords included cryoablation, immune system, 
immunotherapy, melanoma and cancer. Data collection included factors related 
to the synergy between cryoablation and the immune system, cryoablation 
and immunotherapy, effect of cryoablation on tumour tissue and cryoablation 
technique. For immunotherapy, all therapies which could theoretically enhance 
the anti-cancer immune response through either stimulation of the adaptive or 
innate immune system were included. Studies could be performed in patients 
and animals. Articles about combination of different ablation modalities were 
excluded. A total of 45 relevant papers were identified and the most interesting 
and relevant studies were used for this review. To outline this paper, the studies 
were structured by tumour type and the current knowledge about the tumour 
type, cryoablation and immunotherapy was reviewed.
RESULTS
Cryoablation and the immune system
Cryoablation may be synergistic with the immune system in the way cell death is 
induced. After ablation, the tumour remains, releasing various factors attracting 
the immune system. A proposed theory regarding the potential mechanisms 
of cryoablation and the immune system is the danger theory of Matzinger [14, 
15]. This theory proposes that after cell death by necrosis, cells secrete danger 
signals. These danger signals can initiate an immune response. In addition, 
these signals can mature dendritic cells (DCs) to fully activate T cells which 
may lead to a specific immune response. Cryoablation induces cell death by 
necrosis in which intracellular contents are still preserved while DNA, RNA and 
heat shock protein (HSP), which can induce danger signals, are released [16]. 
On the other hand, the cells in the outer margin of cryoablated tissue die from 
apoptosis and do not release DNA, RNA and HSP, and with no danger signal, 
the DCs remain immature. Immature DCs may trigger immune suppressive 
signals that could lead to anergy (T cell inactivation) [17, 18]. Therefore, 
cryoablation can induce both an immunostimulatory and immunosuppressive 
response (Fig. 2). In addition, cytokines are produced after cryoablation, and 
these can also influence an immune response. Again, both immunosuppressive 
and immunostimulatory cytokines may be released depending on the tumour 
tissue, age and freeze rate [19]. For cryoablation of liver tumours, when more 
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than 20% of the liver volume is ablated, a systemic inflammatory response 
can occur due to a release of cytokines interleukine-6 (IL-6), IL-10 and tumour 
necrosis factor alpha (TNFα), which can have marked systemic effects [7, 
20–22]. Therefore, cryoablation is not the preferred treatment since heat-
based ablations are better established in this setting [23]. Yet, two clinical 
studies reported favourable outcomes on overall survival when cryoablation 
was combined with immunotherapy of allogenic natural killer (NK) cell infusion 
and dendritic cell cytokine-induced killer (DC-CIK) cells [24, 25]. Preclinical 
work from den Brok et al. confirms the effect of cryoablation on the immune 
system. This study reported that cryoablation creates an antigen depot resulting 
in maturation of DCs. The maturation of DCs led to a tumour-specific immune 
response protecting half of the mice against a new injection of similar tumour cells.
When cryoablation was combined with an immune checkpoint inhibitor, anti-
cytotoxic T lymphocyte-associated protein 4 (CTLA-4) antibody, this anti-tumour 
effect was further enhanced with up to 80% of the mice becoming tumour free 
[26]. Clinical work by Takaki et al. evaluated peripheral blood after heath- 
and cold-based ablation modalities with pre-treatment (baseline) in different 
tumours showing no change in T cell subtypes (regulatory T cell (Tregs), T1 
helper or Th2 helper cells) in all modalities, an elevation of cytotoxic T cells 
after heat-based ablative treatment was noted, and this was not identified after 
cryoablation [27]. In a group of hepatitis B-positive hepatocellular carcinoma 
patients, the presence of elevated programmed cell death protein 1 (PD-1) on 
T cells and programmed cell death ligand 1 (PD-L1) expression on tumour cells 
had a poor overall survival post cryoablation [28]. Theoretically, when combining 
cryoablation with a PD-1 inhibitor, such as nivolumab or pembrolizumab, the 
cryoablation induced adaptive immune resistance with upregulation of PD-L1 
on tumour cells could be overcome, resulting in an effective anti-tumour T 
cell response. This potential synergy between cryoablation and anti-PD-1 
may result in a more effective disease control; see Fig. 3 [29]. To enhance 
the immunogenicity effect of the cryoablation, different immunotherapies 
can be given as shown in Table 1. Most immunotherapy enhances the innate 
immunity, namely natural killer (NK) cell therapy, dendritic cells (DCs) and CpG 
oligonucleotide (CpG ODN). When cryoablation presents the contents of the 
tumour cells, the innate immune system can assimilate these contents and 
present it to T cells; an immune response specific to the tumour cells could 
be obtained. Table 2 is an overview exhibiting the most studied factors after 
cryoablation in the reviewed papers.
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Table 1. Summary of the major therapies with their mode of action used in combination 
with cryoablation in the reviewed papers. All therapies stimulate the immune system in a 
way and in combination with cryoablation an enhancement of this effect is hypothesized
Therapy Mode of action Number of 
articles
CpG oligonucleotide (CpG 
ODN)
Is recognized by dendritic cells 
(DCs) and B cells. Activates T cells, 
natural killer (NK) cells, monocytes, 
neutrophils and plasma cell 
differentiation
8
Anti-cytotoxic T-lymphocyte-
associated protein 4 (anti 
CTLA-4)
Blocks the inhibitory receptor 
(CTLA-4) on the T cell and therefore 
activates the T cell for a specific 
immune response
6
Immature dendritic cells (DCs) Phagocytosis of pathogens; antigen-
presentation to other immune cells 
(among others T cells)
4
Natural Killer (NK) cell therapy Infusion with autologous NK cells to 
directly kill tumour cells
4
Dendritic cell- cytokine 
induced killer (DC-CIK)
May act like T cells or NK cells 
but is unrestricted to major 
histocompatibility complex (MHC)
3
Granulocyte-macrophage 
colony-stimulating factor (GM-
CSF)
A protein that functions as a cytokine 
and stimulates stem cells and can 
induce an immune cascade
3
Anti-programmed death-ligand 
1 (PD-L1)
Blocks the receptor Programmed 
death -1 on the tumour cell. This 
results in activation of the T cell to 
induce a specific immune response
1
8
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Table 2. Overview of the most studied factors of cryoablation and the immune system 
in the reviewed papers
Most studied factors of cryoablation and the immune system
Mice Total 28 articles
 Survival ↑  17/17
 Rechallenge of primary tumour ↑ 12/12
 Reduction in distant metastasis ↑ 10/10
 Cytokine release ↑ 16/17
 IFN-y release ↑ 16/17
 TNF-α release ↑ 4/5
 IL-4 ↑ 1/7
 IL-10 ↑ 1/4
 Th1/Th2 cytokine ratio ↑ 10/0
 CD4+ infiltration ↑ 12/16
 CD8+ infiltration ↑ 14/19
 Treg ↓ 5/6
 NK cells ↑ 3/4
Human Total 17 articles
 Survival ↑ 8/8
 Quality of Life ↑ 4/4
 Cytokine release ↑ 6/7
 IF- y release ↑ 6/7
 TNF-β release ↑ 3/4
 IL-10 ↓ 3/5
 IL-4 ↓ 3/4
 IL-2 ↑ 3/5
 Th1/Th2 cytokine ratio ↑ 5/0
 CD4+ infiltration ↑ 5/8
 CD8+ infiltration ↑ 5/8
 Treg ↓ 2/2
 NK cells ↑ 4/4
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Breast Cancer
Cryoablation was approved for the treatment of fibroadenomas for over a 
decade [30]. In 2016, the American College of Surgeons Oncology Group 
(ACOSOG) alliance considered cryoablation as an effective treatment for 
unifocal ductal cancer, with a success rate of complete tumour ablation of 
92% after correction for multifocal disease [31]. Also, for the treatment of stage 
IV breast cancer, cryoablation is a safe and effective procedure to control the 
disease and debulks the tumour in the breast [32].
Although antibodies are part of the treatment for human epidermal growth factor 
receptor 2 (HER2)-positive breast cancers, no active forms of immunotherapy 
such as immune checkpoint inhibitors are currently approved for breast cancer. 
Recently, the interim analysis of the Impassion 130 study with the combination 
of nab-paclitaxel plus atezolizumab revealed an impressive 10 months of 
improvement in overall survival compared with chemotherapy alone in PD-L1-
positive triple negative metastatic breast cancers [33]. Other immune checkpoint 
blocking antibodies, such anti-CTLA-4 antibody, are also under investigation [34].
One of the first reports confirming the immunogenicity of cryoablation in breast 
cancer was in a mammary mouse model. After cryoablation or surgery, mice 
were re-challenged with tumour cells and only 16% of the cryoablated exhibited 
tumour development compared to 86% of the surgically treated mice [35]. In a 
metastatic breast cancer mouse model, cryoablated mice treated with a high 
freeze rate (100% cryoablation cycle) showed an improvement in overall survival 
with significant reduction in the number of pulmonary metastasis compared to 
treatment with a low freeze rate (10% cryoablation cycle) or those treated with 
surgery [19]. When cryoablation was combined with injection of CpG ODN (a 
single-strand DNA molecule that acts as a toll-like receptor (TLR) agonist to 
stimulate and mature DCs) in mice, less tumour recurrence and secondary 
tumour growth were seen after the re-challenge compared to the mice that 
received cryoablation alone or surgery [36]. No significant difference was 
reported between CpG ODN alone or in combination with cryoablation groups, 
leaving the added role of cryoablation to CpG ODN injection undetermined 
regarding cytokine release and potential immune activation [36].
Other studies have investigated the combination of cryoablation with an 
immune checkpoint inhibitor (ipilimumab) 7 days before mastectomy in a group 
of patients with early-stage breast cancer. The pilot study, including 19 patients, 
showed that this approach was a safe option without delaying the mastectomy 
[37]. A post hoc analysis was performed to assess the possibility of T cell 
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receptor sequencing as a biomarker for T cell response to cryoablation, where 
no specific T cell response was observed [38]. Additionally, a phase II trial is 
ongoing where cryoablation in combined with ipilimumab and nivolumab before 
breast surgery in triple negative breast cancer patients after taxane-based 
neoadjuvant chemotherapy [39].
In another study, recurrent HER2-positive breast cancer patients were treated 
with the combination of cryoablation, trastuzumab and natural killer (NK) cell 
therapy (intravenous infusion of allogenic NK cells). These patients displayed 
a significantly prolonged progression-free survival (PFS), significantly larger 
numbers of T cells and Th1 cytokines together with a significantly reduction 
in the number of circulation tumour cells in the peripheral blood compared 
to patients only treated with cryoablation alone or cryoablation and NK cell 
therapy. To note, PFS was not reached in the triple combination group, and the 
significantly prolonged PFS could be due to trastuzumab [40].
Niu et al. evaluated the use of cryoablation in combination with immunotherapy 
of DC-CIK cells in metastatic breast cancer patients versus chemotherapy or 
cryoablation alone. The group of patients that received multiple cryoablations 
(several sites) in combination with immunotherapy displayed a significantly 
longer median overall survival compared to the other groups [41].
Together, cryoablation before mastectomy is feasible and its combination 
with immunotherapy, consisting of NK cell therapy, DC-CIK or anti-CTLA-4 
antibody, is safe and effective in different stages in breast cancer. These 
results encourage further investigation into the combination of cryoablation and 
immunotherapy for breast cancer patients. Two trials are currently open which 
combine cryoablation with immune checkpoint inhibitors (Table 3) [42, 43].
Renal cell carcinoma
In RCC, cryoablation is most frequently used to treat stage I cancer (ideally 
smaller than 4 cm taken as the largest diameter) in patients not eligible for 
surgical resection [44, 45]. With optimal patient selection, results similar to 
partial nephrectomy can be achieved [46]. Immunotherapy for RCC has been 
used for quite some time, and nivolumab, a PD-1 inhibitor, is already approved 
for the treatment of RCC [47, 48].
Two animal studies showed the favourable effect of cryoablation in the 
microenvironment of RCC and in the kidney. The first study used two mice 
models, one with and one without injected RCC to observe an inflammatory 
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immune response after cryoablation in the tumour or healthy kidney tissue. 
An infiltration of neutrophils, macrophages and CD4+ and CD8+ T cells 
was reported after cryoablation whereby no difference was observed after 
cryoablation of normal kidney tissue or tumour tissue [49]. Another study 
compared cryoablation with surgery and showed decreased tumour growth 
after the re-challenge of the tumour cells with significantly more T cells in the 
peripheral blood after cryoablation [50].
Kato et al. showed that in half of the patients with T1 RCC, a significant increase 
in T cell receptor (TCR) B CD3 clonotypes of T-cells in post ablation tissue and 
blood was seen with a low diversity (TCR clones were not evenly distributed 
anymore) [51]. In another clinical study, two sessions of cryoablation of the 
pulmonary metastases, each combined with two intratumoural injections of 
granulocyte-macrophage colony-stimulating factor (GM-CSF), resulted in 
higher levels of NK cells, Th1 cytokines and T and B cells in the peripheral 
blood compared to baseline [52].
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Lin et al. showed similar effects of allogeneic NK cell immunotherapy combined 
with cryoablation in 60 advanced RCC patients, and this treatment combination 
resulted in more tumour responses and decrease in Hounsfield units count than 
cryoablation on its own [53].
To summarise, cryoablation of RCC elicits an immune response and can 
be safely combined with GM-CSF and NK cell therapy. Currently, one trial 
is ongoing investigating the synergy of cryoablation with anti-PD-1 therapy 
(tremelimumab), and another trial investigates the effect of ablation of the 
immune system [54, 55].
Prostate cancer
Cryoablation is currently being used to treat stage I prostate cancer. 
Cryoablation could also be considered as salvage treatment for local recurrence 
after radiation therapy. Future perspectives in prostate cancer shift towards 
a more targeted therapy where cryoablation may have an important role in 
prostate cancer [56].
Presently in prostate cancer, the only approved immunotherapy is sipuleucel-T 
(Provenge), a DC-based immunotherapy that sensitises dendritic cells 
with prostate antigens and is used as a therapeutic vaccine [57]. Other 
immunotherapies evaluated have failed to show improvement in overall 
survival [58–60]. Current developments are focusing on immunotherapy for the 
subgroup with defects in DNA-repair mechanisms, which include microsatellite 
instability and breast cancer gene mutations.
Waitz et al. reported a regression in secondary tumour growth with infiltration 
of CD4+ and CD8+ T cells and lower counts of Tregs in mice treated by 
cryoablation and anti-CTLA-4 antibodies [29]. Another study reported that 
the combination of cryoablation with anti-CTLA-4 antibodies reduced distant 
metastasis in mice together with a reduction in the number of Tregs; these were 
lowest on day 14 but returned to normal levels at day 21 [61].
Recently, combination therapy of androgen deprivation plus anti-PD-1, anti-
CLTA-4 or placebo with or without cryoablation demonstrated a delay in distant 
tumour growth and decreased mortality in mice in the trimodal therapy groups 
[62]. Pre cryoablation tissue in high-risk localised prostate cancer patients 
showed elevated numbers of Tregs compared to healthy volunteers. Numbers 
of Tregs decreased significantly after cryoablation in the prostate patients, and, 
conversely, 7 of 12 patients had an increase of suppressive function of Tregs 
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measured by immunosuppressive assay of CD4+CD25+CD127− which was 
linked to the probability of recurrence of the cancer in 2 patients [63].
Another clinical study reported significantly higher cytokines (TNFα and IFN-y) 
levels, increased T cell response to autologous tumour tissue (IFN-y ELISPOT 
assay) after 4 weeks and higher cytotoxic activity of T cells after 4 and 8 weeks 
(measured by luciferase assay) after cryoablation in 20 high-risk prostate 
patients [64]. In patients with metastatic hormone refractory prostate cancer, 
a combination of cryoablation and GM-CSF showed a 70% decrease of PSA 
levels and a median time to progression of 18 months. No correlation was 
seen between the increase tumour-specific T cell responses in the peripheral 
blood and the increased cytolytic activity (measured by luciferase assay) after 
4 and 8 weeks [65].
The addition of cryoablation to androgen deprivation therapy (ADT) in 
30 prostate cancer patients with bone metastases significantly improved 
progression-free, cancer-specific and overall survival compared to 30 prostate 
patients only treated with ADT [66].
No clinical trials have been performed so far to evaluate a combination of anti-
CTLA-4 antibodies with cryoablation therapy in humans. Only immunotherapy 
with GM-CSF has been investigated. Currently, a phase II trial of the 
combination of pembrolizumab and cryosurgery in stage IV prostate patients is 
ongoing. In addition, other trials are ongoing searching for the relation between 
cryoablation and the effect on the immune system [67–70].
Lung cancer
Percutaneous local ablative therapies are considered viable options for the 
treatment of stage IA non-small-cell lung carcinoma (NSCLC). Recurrent 
lesions after radiation therapy or surgery and metastatic lesions can be treated 
by means of ablation as well [71, 72]. Cryoablation of lung lesions is associated 
with lower pain levels and fewer complications in tumours located close to the 
chest wall and mediastinum or central lesions close to the hilum; however, 
no clinical randomized studies have been executed comparing the different 
percutaneous ablative therapies [73, 74].
NSCLC is a heterogeneous group of cancers which is known for high numbers 
of tumour-specific mutations that are linked with response to immunotherapy 
[75]. In recent years, several immunotherapies have been approved for the 
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treatment of lung cancer, namely PD-1 checkpoint inhibitors nivolumab and 
pembrolizumab and the anti-CTLA-4 inhibitor ipilimumab.
Preclinical work in a mouse model revealed that intratumoural injection of 
DCs with cryoablation elicits a Th1 response with higher levels of IFN-y 
and effector memory CD8+ T cells observed from spleen cells resulting in 
protection against secondary tumours and prolonged survival [76]. In another 
study, the addition of CpG ODN to the cryoablation plus DCs resulted in a 
significant reduction of new tumour growth, fewer metastasis development 
and a prolonged survival compared to all the therapies alone. A decrease in 
Tregs and increase in cytotoxic T cells were observed and linked to the better 
response in the combination group [77]. In another study, the same treatment 
combination showed a higher elevation of CD4+ and CD8+ T cells and IL-12, 
IFN-y and TNFα together with a delay in tumour growth and improved survival 
in mice treated with the combination therapy [78]. Takahashi et al. reported 
the greatest immune response (higher numbers of specific T cells and higher 
levels of stimulating cytokines) and the slowest tumour growth after two cycles 
of cryoablation compared to one or three cycles of cryoablation [79].
Clinical work combining cryoablation and allogenic intravenous NK cells showed 
an improvement in the quality of life and tumour response rates compared to 
cryoablation alone. Additional phase II/III trials must be conducted to reveal 
the potential benefits in larger patient groups before combination treatment is 
considered an alternative [80]. Another strategy, consisting of a combination 
of cryoablation with gefitinib, an inhibitor of epidermal growth factor receptor’s 
(EGFR) tyrosine kinase domain, showed significant improvement of overall 
response with a higher 1-year survival rate in patients treated with gefitinib 
and cryoablation compared to gefitinib alone [81]. Lastly, 166 metastatic 
NSCLC patients received either cryoablation alone, cryoablation followed by 
immunotherapy (DC-CIK) or chemotherapy or all three therapies. The survival 
of patients treated with cryoablation combined with chemo or immunotherapy 
was longer than treatment consisting of chemo or immunotherapy alone (18 
and 17 months vs 8.5 and 12 months). The overall survival in patients that 
received the triple combination therapy (cryoablation, immunotherapy and 
chemotherapy) was significantly longer (27 months) compared to other groups 
[82].
These studies show positive results for the combination of cryoablation 
and stimulants to the immune system, NK cell therapy or DC-CIK, with 
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improvement in survival. Clinical results are expected from a phase II study 
where cryoablation is combined with an immune checkpoint inhibitor [83, 84].
Melanoma
Cryoablation is used for the treatment of benign superficial lesions, such as 
actinic keratosis, but it is not indicated as a treatment for primary melanoma. 
Only in unresectable lesions with high metastatic load, cryoablation may 
diminish tumour load by ablation of the primary site [85, 86]. The treatment of 
melanoma metastasis can be performed with cryoablation to slow down the 
rate of tumour spread [87, 88].
In metastatic mouse models, combinations with different immunostimulants 
(including TLR 9 and CPG) have shown an enhanced effect of cryoablation 
for suppression of new tumour growth [26, 89–91]. A pilot study observed the 
induction of endogenous heat-shock protein after administration of GM-CSF 
and radiofrequency ablation or cryoablation in metastatic melanoma patients, 
with a small number of subjects demonstrating the combination therapy as a 
feasible and safe therapeutic option [92].
The combination of cryoablation and immunotherapy may be beneficial in the 
metastatic stetting to overcome the limitations of the immunotherapy. Currently, 
two trials are open combining immunotherapy and cryoablation (Table 3).
CONCLUSION
Cryoablation has proven to be successful for local control in various cancer 
types. Mostly, it is indicated for tumours at an early stage or those not eligible 
for surgery. The synergies of local ablative techniques together with systemic 
treatments are currently one of the most exciting developments of interventional 
oncology. Particularly, given that cryoablation provides a pool of antigens 
visible for the immune system to induce an immune-specific activation directed 
against the tumour cells.
In this review, a total of 41 out of 45 publications show favourable effects for 
cryoablation when combined with other therapies, potentially enhancing the 
anti-cancer immune response. This emphasises the potential advantage of this 
ablation technique as an adjunct with immunotherapy. RCC and NSCLC are 
the neoplasms where cryoablation and its synergy with immunotherapy are 
predominantly studied. Both, immunostimulants for the innate and adaptive 
immune system demonstrate feasibility and effectiveness. For the translation 
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of the results seen in animals and small groups of patients, larger prospective 
trials need to be designed to first study safety and efficacy before moving into 
randomized controlled settings.
In the next 5 years, several pilot, phase I and early II clinical trials currently 
in place will demonstrate whether or not the combination of cryoablation and 
the immune system will have a true beneficial effect. This benefit can come 
from two different approaches that is first the contribution of cryoablation 
to immunological systemic effect of immunotherapy. Second, the impact of 
immunotherapy to overcome the limitations of cryoablation related to the 
upregulation of PD-L1. The features of imaging and molecular biomarkers, 
such as PD-L1 and others will help to optimise the combination strategies.
Furthermore, the strategy of combining cryoablation with new therapeutic 
options (specifically DC vaccine, CAR T cells, oncolytic viruses and adoptive 
T cell transfer) will provide a broader scale of immune-boosting therapies that 
will hopefully translate into the clinics and may thereby provide even better 
outcomes when combined with cryoablation.
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In this thesis, we investigated different interventional oncology (IO) procedures 
in patients with liver metastatic breast cancer (LMBC) and with renal cell 
carcinoma (RCC). We aimed to identify factors associated with safety, efficacy 
and overall survival (OS) to improve treatment stratification in daily clinical 
practice and to develop further studies.
Part I: Intra-arterial therapies for liver metastatic breast cancer
Patients with LMBC undergo systemic treatment; chemo- and/or hormonal 
therapy in receptor-positive patients. The aim is to prolong while maintaining 
a good quality of life. The expected efficacy of the systemic drugs decreases 
with subsequent lines of chemotherapy to only 24% after 3rd line chemotherapy 
in hormone-positive breast cancer patients [1]. In addition, liver metastases 
can cause hepatic dysfunction which may affect the efficacy and safety of 
the systemic chemotherapy [2]. Intra-arterial liver-directed therapies may 
provide a chemo holiday in patients with progressive disease during several 
chemotherapeutic lines or can be effective for chemo refractory patients [3].
To date, the role of intra-arterial therapy in LMBC is not clear and is therefore 
not included in the European Society for Medical Oncology guidelines [4]. This 
is mainly due to the heterogeneous data in literature as shown in our systemic 
review in Chapter 2. The included studies showed that the intra-arterial IO 
therapies were performed at different time points of the disease, with diverse 
(extra) hepatic tumour burden after various lines of chemotherapy. In literature 
these factors have all shown to impact OS [5, 6], and therefore comparison 
between the therapies for LMBC cannot be performed. Given the fact that most 
patients were chemo refractory after several chemotherapy lines, we can at 
least deduce that the efficacy rate of intra-arterial therapies in this group is 
not nihil starting from 8% up to 100%. However, since there is no randomized 
controlled data about the efficacy of intra-arterial therapy in LMBC patients, 
no strong conclusions could be drawn.
In our retrospective evaluation of 176 patients, we showed that intra-arterial 
therapy by MMC infusion is a safe and effective treatment option in an advanced 
LMBC group refractory to systemic chemotherapy (Chapter 3). We obtained 
a local disease control in 58% of the patients at low toxicities. Two patients 
showed renal toxicities, however, no hemolytic uremic syndrome occurred 
among the total of 599 intra-arterial administered MMC infusions. Therefore, we 
concluded that intra-arterial infusion of MMC is safe. After intra-arterial MMC 
treatment, 50% of the treated patients were able to continue their systemic 
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treatment, hence, MMC infusion provided a chemo holiday during which the 
patients could recover from adverse effects of their systemic treatment.
Besides MMC, other intra-arterial chemotherapeutic agents are available. Vogl 
et al. combined MMC with Gemcitabine and achieved a higher response rate 
with low-grade adverse events and a longer OS [7]. To note, only 8.3% of the 
patients had extra-hepatic disease compared to 73% in our study in Chapter 
3. Two other studies that combined several chemotherapeutic agents also 
achieved higher response rates and longer OS compared to our cohort [8, 9], 
although true comparison is difficult because of the heterogeneity of the data.
We found that patients treated with multiple chemotherapy lines, extended liver 
disease consisting of a tumour burden (>50%) or deteriorated liver function had 
a worse OS (Chapter 3). These results might help to improve patient selection 
in daily practice to select patients that benefit most from intra-arterial therapy. 
It should be objectified if patients quality of life (QoL) is indeed better with intra-
arterial therapy compared to systemic therapy.
Breast cancer is a highly heterogenetic disease with many subtypes and 
different prognosis, each treated differently. Our work could not identify a type 
of breast cancer (e.g. hormone positive patients) that would benefit most from 
intra-arterial therapy. Only in an univariate analysis, triple negative receptor 
status was significantly associated with a worse OS. Two studies found an 
association for positive estrogen (ER) receptor status and a lower death 
risk [10, 11]. This is in line with a large study of survival analysis of de novo 
metastatic breast cancer in which ER and PR positive breast cancer patients 
had a lower death risk in an adjusted model in over a 10000 patients [12]. 
Treatment stratification for subgroups of LMBC patients should therefore be a 
subject of further prospective studies.
We showed that the addition of MMC infusion therapy immediately after trans 
arterial radioembolization (TARE) was safe without additional adverse events 
(Chapter 4). However, 30% of the patients developed extra-hepatic disease 
progression after this combination treatment. It is therefore debatable whether 
the sequential intra-arterial therapies of TARE and MMC, would be a valuable 
treatment combination for LMBC. A more interesting question would be if the 
combination of intra-arterial and systemic treatment would be more beneficial 
in terms of local and systemic control compared to solely systemic treatment.
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Martin et al. showed a surprisingly prolonged (47 months) OS in LMBC patients 
treated with the combined TACE of doxorubicin loaded beads and systemic 
chemotherapy. This could be the result of lead-bias in which the follow-up of 
the patients simply started earlier on resulting in a longer OS [13]. Currently, 
the combination of TARE and systemic chemotherapy is under investigation 
in a large multicenter randomized controlled trial for patients with CRLM [14]. 
The results of this trial may be important for further prospective studies to 
prove whether the combination of intra-arterial and systemic therapy would be 
beneficial in terms of PFS and OS in LMBC patients.
The main goal for systemic treatment in LMBC patients is to increase survival 
at tolerable doses and toxicities. With the latter challenges of systemic 
treatment, the addition of intra-arterial therapy can potentially provide a break 
in chemotherapy to recover from severe adverse events. Intra-arterial treatment 
after failure of systemic treatment may provide patients a better local control 
with better quality of life.
Part II: Percutaneous ablation in renal cell cancer
The European Association of Urology (EAU) guidelines for RCC recommends 
partial nephrectomy (PN) as first-line treatment for stage T1 disease. 
Candidates less optimal for surgery could be considered for minimal invasive 
IO therapies such as percutaneous ablation [15]. Available literature comparing 
percutaneous ablation with PN contain a high selection bias, in which the 
elderly are selected for ablation, which potentially skews towards a lower 
survival [16]. Several RCT’s are running comparing ablation with PN [46].
In contrast to surgery for renal masses, after percutaneous ablation no 
specimen is available after the procedure to confirm malignancy and to prove 
complete eradication of the tumour with free margins. Therefore a renal mass 
biopsy (RMB) before or during the ablation procedure is needed. In Chapter 5, 
we showed that RMB performed during a separate session from the ablation 
session reduces overtreatment in patients with a renal mass. Others evaluated 
the performance of an RMB either before or during the ablation, but included 
patients who all underwent ablations and no changes in clinical management 
could be reported [17, 18]. In our cohort we included all patients planned for 
ablation, treated or non-treated. We found that up to 80% of the patients with a 
biopsy proven benign renal mass chose not to proceed to the ablative therapy. 
Hence, performing an RMB in a separate session before the ablation provides 
an opportunity for the physician to inform the patient on the benefits and risks 
and facilitates a shared decision making. In addition, such a regimen resulted 
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in unnecessary treatment in 32.5% of the patients. Potential overtreatment 
of benign renal masses is of great concern in comorbid patients with higher 
mortality risk due to causes other than their benign renal mass.
Compared to radiofrequency ablation (RFA), microwave ablation (MWA) 
achieves higher energies from a single probe and is therefore less influenced 
by the heat sink effect [19]. The heat sink effect is the influence of nearby blood 
vessels that lower the temperature within the ablation zone and decrease the 
efficacy [20]. In chapter 6, we concluded that MWA is a safe and effective 
ablation technique for cT1 RCC with a significantly lower efficacy and safety 
for cT1b tumours compared to cT1a tumours. We showed that the tumour size 
and location in proximity to the collecting system, indicated as the modified 
R.E.N.A.L. nephrometry score, influenced oncological outcome after MWA.
Smaller exophytic lesions showed excellent efficacy and safety rates after 
MWA, which is in line with the available evidence [21]. Recurrence after 
ablation can occur late (Chapter 6), therefore extensive follow-up is required 
by consecutive imaging using contrast enhanced computed tomography (CT), 
which is less ideal in younger patients. Younger patients should therefore best 
be treated with surgery.
Lower efficacy rates of percutaneous ablation are described for tumours over 
4 cm which is in line with our findings [22]. Our cohort contained large lesions 
at challenging locations, e.g. nearby the collecting system, which were treated 
with MWA as last treatment option. We experienced that MWA for large lesions 
was feasible, but since 50% had residual disease a second ablative treatment 
following MWA should be considered beforehand.
Shapiro et al. compared MWA with partial or radical nephrectomy in T1b 
tumours and MWA was 95% effective and recurred in 5% [23]. An important 
difference is that the new MW system was used in Shapiro’s study, the 
NeuWave system, in which multiple probes can be placed at once leading 
to a synergistically improved development of the ablation zone compared to 
placement of each probe on its own. Future studies have to prove whether the 
NeuWave is indeed superior to the standard MW system taken the tumour size, 
location and physician experience into account.
During cryoablation (CA), multiple probes can be used to develop a large 
ablation zone resulting in tumour control in lesions up to 7 cm [24]. Several 
reports also suggest that CA protects the renal collecting system in a greater 
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extent than RFA and MWA, whereby ablation of endophytic lesions is possible 
without major adverse events [25, 26]. Since April 2018 we have a CA system 
available in our hospital, which gave us the opportunity to re-ablate patient 
using a different ablation technique if MWA fails. In Chapter 7 we showed that 
CA is feasible after failure of MWA in endophytic lesions with complete ablation 
achieved in eight out of nine patients with only two minor adverse events in this 
complex tumours. During a follow-up of at least one year, 66% of our patients 
remained disease free. Therefore CA offered a nephron sparing minimal 
invasive treatment in this group of patients for whom radical nephrectomy can 
be avoided.
From an extensive literature review of CA and immunotherapy in Chapter 8, we 
found that most preclinical reports suggest that CA induced a systemic immune 
effect and enhance immunotherapies, also called the abscopal effect. However, 
limited data was available in humans and more studies are necessary to prove 
this benefit. If proven promising, an abscopal effect of CA when combined 
with immunotherapy, could be a way to overcome immune suppression and to 
increase efficacy of immunotherapy in advanced disease, potentially increasing 
OS. With the increasing evidence of effective immunotherapy both in adjuvant 
and neoadjuvant setting it will be interesting to see whether or not CA will have 
a role in immunotherapy and future studies are needed.
Conclusions:
This thesis shows the safety and efficacy for interventional oncology procedures 
in LMBC patients and patients with RCC.
We showed that intra-arterial therapy by MMC infusion is safe and effective 
in an advanced LMBC group refractory to systemic chemotherapy. With the 
challenges of systemic chemotherapy regarding toxicity and efficacy, the 
addition of intra-arterial therapy may be a promising step to provide a break 
during the systemic treatment (chemo-holiday) or serve as treatment option in 
chemo refractory LMBC. Patients treated after several lines of chemotherapy, 
with extended liver disease, a tumour burden of over 50% or deteriorated liver 
function, had a poor OS. A sequential treatment of TARE and intra-arterial 
MMC infusion is feasible in LMBC patients, but we believe that this is not the 
best treatment regimen due to observed progression of extra-hepatic disease 
in 30%. A combination of intra-arterial therapy with systemic therapy could 
perhaps be more beneficial and should be a subject of future studies in LMBC.
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Percutaneous ablation is an effective alternative treatment to partial 
nephrectomy (PN) in T1a RCC with minimal adverse events. Several RCT’s 
are running to prospectively compare ablation with PN. We showed that 
performance of a renal mass biopsy (RMB) during a separate session before 
the ablation procedure can reduce overtreatment of patients with benign 
masses. MWA is a safe and effective ablation technique for cT1a RCC, however, 
a significantly lower efficacy and safety was found for cT1b. Additionally, we 
showed that the tumour size and location (proximity to the renal collecting 
system) of the tumour indicated as the mRENAL nephrometry score, influenced 
oncological outcome after MWA. CA was feasible after failure of MWA in 
endophytic lesions and resulted in complete ablation in 66% of the patients 
with these challenging tumours.
This thesis also stresses the need for high-level evidence for Interventional 
Oncology procedures to understand its position within the spectrum of local 
therapies such as surgery and external beam irradiation. Collaboration with 
other disciplines is essential in a multidisciplinary approach to select the best 
treatment. Ideally, RCT’s comparing the different treatment modalities are 
necessary to provide high evidence data regarding efficacy and survival of the 
treatments, although remain a challenge because of the relatively small sample 
sizes, heterogeneity in patients and in treatments. Prospective registries and 
cohort studies have in the mean-time to function as the best ways to learn 
from these therapies.
Recommendations:
Based on our work and in the context of available evidence, we have the 
following recommendations for clinical practice:
In advanced LMBC patients, progressive after multiple lines of systemic 
chemotherapy, MMC infusion could be considered as a local treatment to 
provide a chemo holiday.
Intra-arterial therapy can be considered as treatment option in chemo-refractory 
LMBC patients.
Patients with a renal mass planned for percutaneous ablation should undergo 
biopsy in a separate session prior to the ablation to confirm malignancy.
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Partial Nephrectomy (PN) remains the standard treatment for T1 RCC. However 
patients less eligible for PN could be referred for percutaneous ablation.
For patients with a peripheral T1a RCC, MWA should be considered as upfront 
treatment. Because of the increased risk of incomplete ablation with MWA, 
especially in large and central tumours, sub sequent completion therapy such 
as cryoablation or surgery should be taken into consideration.
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English summary
The aim of this thesis was to investigate different interventional oncology 
procedures for the management of local control in liver metastatic breast 
cancer (LMBC) patients (Part I) and patients with renal cell carcinoma (RCC) 
(Part II).
Part I: Intra-arterial therapies for liver metastatic breast cancer
In chapter 2, we performed a systematic review to assess the evidence of 
intra-arterial therapies in LMBC patients on response rate, adverse events 
(AEs) and overall survival (OS). We described that the 29 included studies 
show promising results although high level evidence is lacking. The outcomes 
differed widely between all studies, due to a pronounced heterogeneity of 
the patient populations, treatment protocols and response evaluation which 
impaired direct comparison between the therapies. The combination of an intra-
arterial therapy and systemic treatment yielded the longest OS, probably due 
to lead-bias, but suggest the opportunity for the combination of intra-arterial 
therapy and systemic chemotherapy.
In Chapter 3 we analyzed the safety, efficacy and factors influencing outcome 
of Mitomycin C (MMC) infusion in 176 heavily pre-treated LMBC patients of the 
University Hospitals (UZ) Leuven between 2000 and 2017. We showed that 
hepatic disease control was obtained in 58% with only 17.5% AEs grade ≥3 and 
a median OS of 7.8 months. An increased number of prior therapies, a higher 
liver tumour burden and elevated levels of bilirubin and ALT were associated 
with a worse OS. These findings may help to improve patient selection in future 
studies. Fifty percent of the patients was eligible for systemic therapy after 
the MMC infusions. We therefore concluded that MMC infusion is a safe and 
effective treatment option in advanced LMBC patients.
Chapter 4 shows the results of a feasibility study performed in UZ Leuven of the 
sequential treatment of intra-arterial MMC infusion in four escalating cohorts 
after selective internal radiation therapy (SIRT) using Yttrium-90 (90Y) resin 
microspheres in LMBC patients. The sequential treatment was possible in 12 
out of the 16 patients with no additional AEs after the escalating MMC infusions. 
One grade 3 AE occurred after 90Y SIRT and consisted of a gastrointestinal 
ulcer with consequently exclusion of further MMC infusions. We concluded that 
sequential treatment of intra-arterial infusion of MMC after 90Y SIRT is feasible 
when MMC is administrated in different escalating dose cohorts. However, 
caution is needed to prevent reflux after 90Y SIRT in LMBC patients.
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Part II: Percutaneous ablation in renal cell cancer
In Chapter 5 the difference between renal mass biopsy (RMB) performed 
either before or during the ablation procedure was assessed in a multi-center 
retrospective analysis of 714 patients. Patients that underwent an RMB before 
the planned ablation with a benign pathology result decided to not undergo 
the ablation in 80%. Performance of an RMB during the ablation procedure 
led to potentially unnecessary ablation of renal masses in 32.5%. Performing 
an RMB before the planned ablation therefore reduces overtreatment and 
allows patients and physicians to adjust clinical management according to the 
histological RMB results.
In chapter 6, we evaluated the efficacy and safety of microwave ablation (MWA) 
in 100 patients with stage cT1 renal cell carcinoma (RCC). MWA was a safe and 
effective treatment in cT1a tumours and a significantly lower primary efficacy 
and safety was found in cT1b lesions whereby 48% of the T1b lesions received 
another treatment for local control. The m.R.E.N.A.L nephrometry score 
showed a significant independent association with an incomplete ablation. 
Five patients developed an urinary tract stenosis in central lesions whereby 
close monitoring of the urinary tract is recommended in ablation of tumours 
adjacent to the urinary tract.
In Chapter 7, we show the results of nine patients with a renal mass treated by 
cryoablation (CA) for their residual or recurrent disease after prior MWA. CA 
showed a complete ablation in 8 patients with only two minor AEs in a cohort 
of challenging lesions. During a follow-up of at least one year, 66% of the 
patients remained disease free and therefore CA offered a minimally invasive 
nephron sparing treatment option in most patients with the attempt to avoid 
radical nephrectomy and preservation of kidney function.
In Chapter 8, we reviewed the current evidence of the combination of CA with 
immunomodulatory drugs (immunotherapy). A total of 41 out of 45 publications 
show favorable effects for CA when combined with other therapies, potentially 
enhancing the anti-cancer immune response. RCC and NSCLC were the 
neoplasms where CA and its synergy with immunotherapy are predominantly 
studied. Both, immunostimulants for the innate and adaptive immune system 
demonstrate feasibility and effectiveness. For the translation of the results 
seen in animals and small groups of patients, larger prospective trials need to 
be designed to first study safety and efficacy before moving into randomized 
controlled settings.
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Het doel van deze thesis was om verschillende oncologische interventie 
procedures te evalueren op effectiviteit en veiligheid in borstkanker patienten 
met levermetastasen en niercelcarcinoom. Deel I evalueert verschillende 
intra-arteriële therapieën voor de behandeling van borstkanker patienten met 
levermetastasen. In deel II onderzochten wij de rol percutane ablatie in de 
behandeling van niercelcarcinoom.
Deel I: Intra-arteriële therapieën voor borstkanker patienten met lever-
metastasen
Hoofdstuk 2 geeft een systematisch overzicht weer van de beschikbare literatuur 
van intra-arteriële therapieën in borstkanker patienten met levermetastasen op 
de uitkomsten effectiviteit, veiligheid en algemene overleving. Wij concluderen 
dat de 29 geïncludeerde studies veelbelovende resultaten bevatten, hoewel 
gerandomiseerd bewijs momenteel ontbreekt. De uitkomsten van de studies 
waren uiteenlopend met onder andere, heterogene patiënten populaties, 
behandelprotocollen en respons beoordelingen, waardoor vergelijking niet 
mogelijk was. De combinatie van een intra-arteriële therapie en systemische 
behandeling resulteerde in de langste algemene overleving, waarschijnlijk door 
lead-time bias, echter suggereert dit een potentiële kans voor een succesvolle 
combinatie therapie.
In hoofdstuk 3 hebben wij de effectiviteit en veiligheid van Mitomycine C (MMC)-
infusies geanalyseerd in 176 hevig voorbehandelde borstkanker patienten met 
levermetastasen patiënten in het universiteit ziekenhuis (UZ) Leuven van 2000-
2017. De MMC-infusies resulteerden in een lokale ziekte controle van 58% met 
slechts graad 3 complicaties of hoger bij 17.5% en een mediane algemene 
overleving van 7.8 maanden. Een verhoogd aantal eerdere systemische 
therapieën, een hogere levertumorbelasting en verhoogd niveau van bilirubine 
en ALAT waren geassocieerd met een slechtere mediane overleving. Deze 
bevindingen kunnen bijdragen aan een verbetering in de patiëntenselectie van 
toekomstige studies. Vijftig procent van de patiënten kwam in aanmerking voor 
systemische chemotherapie na de MMC-infusies. We concludeerden daarom 
dat MMC-infusies een veilige en effectieve behandelingsoptie is bij gevorderde 
lever gemetastaseerd borst kanker patiënten.
Hoofdstuk 4 toont de resultaten van een haalbaarheidsstudie naar de 
sequentiële behandeling van intra-arteriële MMC-infusies in 4 escalerende 
cohorten na selectieve interne radiatie therapie (SIRT) met behulp van 
Yttrium-90 (90Y) harsmicrosferen in borstkanker patienten met levermetastasen 
patiënten uitgevoerd in UZ Leuven. De sequentiële behandeling was mogelijk 
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in 12 van de 16 patiënten zonder additionele complicaties na escalatie van de 
MMC infusies. Slechts één graad 3 complicatie trad op na 90Y SIRT bestaande 
uit een maagulcus met als gevolg uitsluiting van verdere MMC-infusies. We 
concludeerden dat sequentiële behandeling van intra-arteriële infusie van 
MMC na 90Y SIRT haalbaar is wanneer MMC wordt toegediend in verschillende 
escalerende dosiscohorten. Voorzichtigheid is echter geboden om reflux na 90Y 
SIRT bij borstkanker patienten met levermetastasen te voorkomen.
Deel II: Percutane ablatie voor de behandeling van renaal cel carcinoom
Hoofdstuk 5 analyseert het verschil tussen het uitvoeren van een biopsie 
vóór of tijdens de ablatieprocedure op overbehandeling en follow-up, in een 
multicenter retrospectieve analyse van 714 patiënten met een niermassa. 
Patiënten die vóór de geplande ablatie een biopsie ondergingen met een 
goedaardig histologisch resultaat, besloten in 80% de ablatie niet te ondergaan. 
Biopten tijdens de ablatieprocedure leidden tot een potentieel onnodige ablatie 
van niermassa’s in 32,5%. Het uitvoeren van een biopt vóór de geplande ablatie 
vermindert daarom overbehandeling en stelt patiënten en artsen in staat de 
klinische behandeling aan te passen aan de histologische biopsie resultaten.
In hoofdstuk 6 evalueerden we de werkzaamheid en veiligheid van 
microgolfablatie (MWA) in 100 patiënten met stadium T1 renaal cel carcinoom. 
MWA was een veilige en effectieve behandeling voor T1a tumoren. Een 
significant lagere primaire effectiviteit werd gezien in T1b tumoren, waarbij 48% 
van de T1b tumoren (>4cm) nog een additionele behandeling moest ondergaan 
voor lokale controle. De m.R.E.N.A.L-nefrometrie score toonde een significante 
onafhankelijke associatie met een onvolledige ablatie. Vijf patiënten met een 
centrale laesie ontwikkelden een urinewegstenose, met nierfunctie verlies in 
twee patiënten. Voorzorg is daarom geadviseerd in centrale laesies met een 
nauwe relatie tot het pyelocalicieel systeem.
Hoofdstuk 7 toont de resultaten van negen patiënten behandeld met cryoablatie 
(CA) vanwege hun residuele of terugkerende renaal cel carcinoom na het 
eerder falen van MWA. CA liet een complete ablatie zien in 8 van de 9 patiënten 
met slechts laaggradige complicaties in een serie met gecompliceerde laesies. 
Tijdens een follow-up van ten minste één jaar bleef 66% van de patiënten lokaal 
ziektevrij. CA bood een minimaal invasieve nefronsparende behandelingsoptie 
voor de meeste patiënten met als doel een radicale nefrectomie te voorkomen 
en de nierfunctie te behouden.
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In hoofdstuk 8 hebben we de beschikbare literatuur uiteen gezet over de 
combinatie van CA met immunomodulerende geneesmiddelen (waaronder 
immunotherapie). In totaal toonden 41 van de 45 publicaties gunstige effecten 
voor CA in combinatie met immunomodulerende geneesmiddelen en een 
versterkend immuunrespons werd gesuggereerd bij de combinatie van CA met 
immunotherapie. Niercelcarcinoom en niet-kleincellig longcarcinoom waren de 
kankersoorten waarin CA en de synergie met immunotherapie voornamelijk 
werd bestudeerd. Immunomodulerende geneesmiddelen voor zowel het 
aangeboren als adaptieve immuunsysteem toonden haalbaarheid en effectiviteit 
aan in combinatie met CA. De geïncludeerde studies bestonden vooral uit 
preklinische studies of zeer kleine klinische studies, waarbij grotere prospectieve 
onderzoeken nodig zijn om de veiligheid en werkzaamheid aan te tonen voordat 
deze combinatie in een gerandomiseerde setting kan worden bestudeerd.
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Since cancer is the second leading cause of death worldwide, research towards 
improvement of diagnosis and treatment stratification is needed. During the 
recent years, the treatment of cancer has improved the survival rates of 
cancer patients tremendously. However, it has been stated that cured cancer 
patients have a poorer quality of life as a consequence of the late effects of the 
treatments. Subsequently, minimally invasive treatments with lower morbidity 
rates have been increasingly adopted as treatment option for cancer care.
Interventional oncology (IO) uses image-guided procedures with the aim 
to prolong survival and maintain quality of life. During the last decade, IO 
procedures have frequently been used in clinical practice and are adapted in 
several international guidelines. IO procedures are able to provide the diagnosis 
of cancer by performing biopsies, treat patients in a curative or palliative setting 
and provide symptom control. Almost every cancer patient undergoes one sort 
of IO procedure and improvement of these procedures are therefore essential 
for cancer patients.
To provide minimal invasive IO treatment, data is necessary to select the 
best patient population to achieve the highest efficacy rates. In this thesis, we 
investigated the efficacy and safety of intra-arterial liver directed therapies in 
liver metastatic breast cancer (LMBC) patients and percutaneous ablation in 
patients with renal cell carcinoma (RCC). We analyzed relatively large cohorts, 
enabling us to determine factors influencing the outcome of the interventional 
oncology procedures.
Part I: Intra-arterial therapies for liver metastatic breast cancer
Breast cancer is the second most diagnosed cancer type and the fourth cause 
of death in the Netherlands. When breast cancer is diagnosed at an early stage 
of the disease, curation is often possible. Contrary, LMBC has a poor prognosis 
with survival rates up to 3 years. Standard treatment for LMBC is systemic 
treatment by means of chemotherapy or (hormone) targeted treatment. Many 
patients develop toxicities from the chemotherapy which impairs quality of life or 
become chemo refractory to the systemic treatment. Intra-arterial therapies are 
liver directed IO procedures performed under image guidance to provide local 
control in the liver at minimal side effects that can be administrated in chemo 
refractory LMBC patients or function as chemo holiday in LMBC patients.
In the Netherlands, intra-arterial therapies are registered for patients 
with primary liver tumours, colorectal liver metastases or neuroendocrine 
neoplasma. To date, intra-arterial therapies are not regularly performed as 
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treatment in the Netherlands in LMBC patients, mainly because LMBC patients 
often have extra-hepatic disease and will consequently only receive chemo 
or targeted therapy. However, liver metastases may cause impairment of liver 
function and therefore especially endangers the patient’s life. Intra-arterial 
therapy can than function as a minimal invasive technique to control the liver 
metastases and improve quality of life. With the results of this thesis, the 
awareness of this treatment option for LMBC patients has increased in Europe 
and the Netherlands.
Mitomycin C (MMC) infusion is an intra-arterial therapy whereby a 
chemotherapeutical (MMC) is administrated via intra-arterial access in the 
hepatic arteries every four weeks. It is a relatively easy and inexpensive 
procedure for interventional radiologists that can be performed in many centers 
in the Netherlands. Only a one-day hospital observation is required for this 
procedure and most patients experience these treatments as innocent with 
resume of daily life within a few days. Intra-arterial therapy by MMC infusion is 
not a new innovative procedure, but expands the toolbox of treatment options 
for LMBC patients with a minimal invasive treatment option.
This thesis added to the knowledge of MMC infusions by reporting on one 
of largest cohort of LMBC patients treated with MMC. We determined which 
patients benefit the most from the intra-arterial therapy and observed a worse 
overall survival in patients with an increased number of prior therapies, upfront 
deteriorate liver function and excessive tumor burden. Our data has been 
presented at (inter) national congresses to achieve recognition for this therapy. 
With these results, we can further implement MMC infusion in the Netherlands 
and determine in advance which patients may benefit the most from the 
treatment. Furthermore, interventional radiologists can council patients in 
advance of the MMC infusion with expectations based on a large cohort.
This thesis also includes an innovative treatment combination of two intra-
arterial therapies which was not reported before in LMBC patients. We showed 
that sequential therapy by MMC and Yttrium-90 is feasible and safe. Patients 
with liver dominant disease can be treated for a longer period by intra-arterial 
therapy to control the liver disease. However, 30% of the patients could not 
receive the combination treatment due to extra-hepatic disease progression. 
This raises the question if the sequential treatment of two intra-arterial 
therapies is the best treatment option. Maybe a combination with systemic 
treatment would be more beneficial for LMBC patients. With these reports 
important factors have been determined to develop future studies for LMBC 
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patients and hopefully inspires more clinicians to use intra-arterial therapies 
in LMBC patients.
Part II: Percutaneous ablation in renal cell cancer
Patients with stage I RCC have excellent outcomes with 10-year survival rates 
between 95 and 100% after elimination of the tumour. In the past decade a 
more minimal invasive nephron sparing treatment approach has therefore been 
accepted as a treatment option. Patients that were previously treated with 
removal of the entire kidney (radical nephrectomy), can now undergo a partial 
nephrectomy (PN). Compared to PN, percutaneous ablation is associated with 
a lower comorbidity and mortality with excellent preservation of the kidney 
function.
During percutaneous ablation extreme high or low temperatures are conducted 
via needles for tumour destruction. Over the last years, percutaneous ablation 
has increasingly been used for treatment of small renal masses. Patients 
treated by percutaneous ablation have a reduced number of hospital day 
admissions and lower complications rates compared to PN. In this thesis, we 
defined some of the factors that may add to the knowledge of percutaneous 
ablation and provide the least invasive treatment for RCC patients.
We showed that by performing the biopsy before the planned ablation 
procedure, patients have the opportunity to deliberate on the treatment with the 
physician, thereby reducing overtreatment and providing essential information 
for treatment stratification. The outcome of this study affected the management 
of RCC patients in clinical practice of the renal cancer network Amsterdam. 
Patients with a T1a RCC whom are planned for ablation now first undergo 
a biopsy, as opposed to previous management in which patients received a 
biopsy during the ablative treatment. In the future also other centers in the 
Netherlands will adopt this management, which will reduce unnecessary 
treatments of patients with a renal mass in the Netherlands.
Microwave ablation (MWA) is a relatively newer ablation technique with less 
reports available. In chapter 6 we showed that MWA is a safe and effective 
treatment for T1 RCC and is most effective and safe in smaller peripheral 
tumours. We determined that size and location are key to obtain a complete 
treatment in MWA. Hence, our results will help to select the right patient for 
the best oncological outcome in T1 RCC and hopefully motivate physicians to 
use the MW system for renal ablations in this patient population.
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Percutaneous ablation is not generally accepted and widely used as treatment 
in T1b tumours with limited reports available. This thesis describes two ablation 
techniques for large tumours, namely; MWA and cryoablation. We showed 
that MWA for T1b lesions was feasible, only 50% of the patients needed a 
subsequent treatment following MWA which should be considered beforehand. 
In addition, we reported the outcome of patients whom were treated with 
cryoablation after failure of MWA with a 100% success rate in four patients 
with a T1b tumours. Our results are promising for cryoablation in T1b tumours, 
yet larger reports are needed. This thesis therefore functions as inspiration for 
future research for minimal invasive treatment option in RCC patients.
Last, another innovative treatment modality has been described in this thesis, 
namely the combination of cryoablation and immunotherapy. Immunotherapy 
has showed a remarkable survival gain for several cancer types. Unfortunately, 
not all patients respond to the immunotherapy, due to, among others, 
escapement of cancer cells to the immune system. Percutaneous ablation 
may prime the immune system by providing a pool of cancer specific antigens 
that can initiate a specific immune response against the cancer cells. This 
thesis investigated the evidence of cryoablation and immunotherapy in different 
cancer types. Most included studies in the critical review described a positive 
effect of the combination therapy regarding survival and implies that future 
research in this field might be of great benefit.
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zonder jullie inzet, steun en vriendschap was mijn thesis en PhD tijd 
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fantastic ideas. Although you have two jobs in two different countries, you 
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amount of trust in me, thank you for everything my friend!   
Beste Lisa, vanaf dag één werd jij mijn voorbeeld, als jonge vrouwelijke 
interventieradioloog met een groot wetenschappelijk brein. Jij bent een 
fantastisch betrokken begeleider, ook persoonlijk, die altijd tijd voor mij 
maakt naast de drukke kliniek. Jouw snelle klinische en gestructureerde 
wetenschappelijke inzichten hebben mij geholpen om deze thesis af te ronden 
in een korte tijd. Na onze meetings kon ik altijd weer met bakken energie verder, 
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Prof. dr. G. Maleux, beste professor Maleux, bedankt voor de begeleiding 
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jullie praktijk te mogen bekijken.      
Prof. dr. R.C. Dresen, beste Elleke, bedankt voor alle hulp bij het RECIST 
scoren en het meedenken over de studies.      
Prof. dr. H. Wildiers, beste professor Wildiers, hartelijk dank voor de 
samenwerking en het delen van uw ervaringen met borstkanker patienten met 
levermetastasen.
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Dank voor jullie betrokkenheid bij mijn promotie traject. Beste Axel, bedankt 
voor de samenwerking binnen de nierkanker. Ik heb veel mogen leren van jouw 
deskundigheid en niet te vergeten het bezoek in Royal Hospital in Londen. 
Beste Marleen, jij was een betrokken OOA lid en een voorbeeld om mee te 
werken, bedankt!
Mijn paranimfen: drs. S.E. Vollenbrock en mr. Q.A.M. Broekema. Met jullie 
aan mijn zijde weet ik zeker dat het goed gaat komen op deze dag!   
Lieve Soof, wat was het een feest met jou als collega! Niet vaak maak 
je mee dat je zo snel met iemand op één lijn zit. Veel meer hoef ik 
hier niet over uit te weiden, ik heb genoten van alle tijd samen en daar 
komen ongetwijfeld nog heel veel mooie herinneringen bij!    
Lieve Q, ik mag van geluk spreken met zo’n lieve betrouwbare vriendin aan mijn 
zijde. Altijd lachen samen, maar ook als het even tegen zit ben jij er voor mij. 
Weinig advocaten die zo veel van alle PhD struggles af weten!
Dr. J.S.A. Belderbos, lieve José, via jou maakte ik al vroeg in mijn studie kennis 
met het AvL en het artsenvak. Je gaf mij inspiratie hoe je het vak kan invullen 
als arts en onderzoeker om kankerpatiënten verder te helpen. Tijdens mijn PhD 
gaf jij mij elke keer het zetje om een stapje verder te zetten, bedankt voor alles!
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Alle collega’s, de PhD studenten en radiologen van het tuinhuis, bedankt 
voor de top tijd waarbij ik altijd bij jullie terecht kon voor een vraag, 
menig small talk of goede discussie!       
Jorrita, zonder jouw ondersteuning en aanwezigheid is het tuinhuis 
gewoon niet hetzelfde! Zuhir, thank you for all your help, always open 
for questions despite your own busy schedule. Prof. dr. Nguyen-Kim, it 
was very special to have you as a colleague; a true inspiration! Ieva, your 
knowledge about IR helped me considerably.    .  
Ezgi, babe, je was een top hulp voor mijn sollicitatie en een super fijne collega 
om mee samen te werken, daarnaast ben je altijd in voor een gezellige 
borrel of hapje eten!         
Lieve Marit, al ging jij snel weg uit het tuinhuis en nam ik jouw plekje over, 
wij zagen elkaar alleen maar meer! Gewaagd aan elkaar op de tennisbaan 
en dansvloer, ik ben blij dat ik er een altijd eerlijke en gezellige vriendin bij 
heb!          
En dan natuurlijk mijn lieve kamergenoten aka de relativeerberen: Sophie, 
Maurits, Lisa, Femke, Charlotte, jullie waren fantastische collega’s! Samen 
in ons hok maakten we de ups en downs van elkaar mee en kon ik altijd terecht 
bij jullie; bedankt!
Al mijn lieve vrienden en vriendinnen, bedankt voor alle welkome afleiding.
Mijn (schoon)familie: Bas en Lilian, Sebas en Juul, Lavinia en Steven, bedankt 
voor jullie interesse en medeleven!
Lieve sissies, de afgelopen jaren hebben wij een bijzondere band opgebouwd 
waar ik onwijs veel waarde aan hecht. Marijke; ondanks jouw drukke baan en 
sociale leven maak je altijd ook tijd voor mij. Jouw andere kijk op zaken helpt mij 
altijd! Annemiek; ook al ben jij mijn kleine zusje, je voelt als een gelijke vriendin. 
Wij kunnen altijd bij elkaar terecht, vooral nu wij zo dicht bij elkaar wonen!
Lieve pap en mam, jullie onvoorwaardelijke liefde en steun hebben mij de 
mogelijkheid gegeven om dit alles te bereiken. Ik hoop dat ik nog lang van jullie 
mag genieten, op nog vele mooie en bijzondere momenten samen!
En dan als laatste en voor mij het meest speciaal en belangrijk; lieve Derk, jij 
staat echt altijd klaar voor mij! Al heb jij niet aan de inhoud mee geholpen, zeker 
wel aan alle bijkomende zaken. Ik ben super trots wat wij beide hebben bereikt 
de afgelopen 10 jaar, het allerbelangrijkste; een geweldig leven samen!
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